PRMT5-MTA inhibitor
Patent Information
- Application Number
- MYPI2025004289
- Authority / Receiving Office
- MY · MY
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-12-08
- Filing Date
- 2024-01-11
- Publication Date
- 2024-07-17
AI Technical Summary
Existing PRMT5 inhibitors have strong inhibitory activity on both normal cells and tumor cells, leading to hematological toxicity, limiting their clinical application, and there is a lack of effective and selective PRMT5-MTA inhibitors.
A new class of compounds has been developed, which are designed through specific functional group structures (such as X1, Sexually inhibits PRMT5 activity.
It achieves efficient inhibition of PRMT5 activity in tumor cells, reduces the inhibitory effect on normal cells, improves treatment safety and anti-tumor effect, and has good metabolic stability and membrane permeability.
Abstract
Description
PRMT5-MTA inhibitors Technical Field
[0001] The present invention belongs to the field of medicine, and particularly relates to a PRMT5-MTA inhibitor. Background Art
[0002] Protein arginine methyltransferase (PRMT) can methylate histones and non-histones, thereby participating in the regulation of biological processes such as gene transcription, signal transduction, protein stability, cell proliferation, differentiation, apoptosis, and tumor formation (Nat Rev Mol Cell Biol. 2019 Oct; 20(10): 642-657)(Nat Rev Drug Discov. 2021 Jul; 20(7): 509-530). Currently, 11 PRMT family members have been discovered, which can be divided into types I, II, and III according to the different ways they catalyze arginine methylation. Among them, PRMT5 belongs to type II, and its catalytic form is symmetrical dimethylation.
[0003] As an epigenetic enzyme, PRMT5 is involved in a variety of biological processes, including transcriptional regulation, RNA metabolism, ribosome biogenesis, and cell cycle regulation. PRMT5 protein is overexpressed in a variety of cancer types, including B and T cell lymphomas, metastatic melanoma, neuroblastoma, glioblastoma, ovarian cancer, and breast cancer. Growing evidence suggests that it plays an important role in tumorigenesis and progression (Cell Stress. 2020 Aug; 4(8): 199–215)(Cancer Gene Ther. 2022 Mar; 29(3-4): 264-276.). Based on this, PRMT5 inhibitors have become a hot topic in the research and development of tumor treatment drugs.
[0004] Early PRMT5 inhibitors can be divided into two categories: one is substrate-competitive inhibitors, represented by GSK3326595; the other is SAM-competitive inhibitors, represented by JNJ64619178. Both types of drugs have strong inhibitory activity against PRMT5 and show strong anti-tumor activity. However, due to their strong inhibitory activity against PRMT5 in both normal cells and tumor cells, strong blood toxicity has been observed, which limits their clinical application and thus affects their clinical therapeutic effects (Bioorg Med Chem Lett. 2019 Jun 1; 29(11): 1264-1269)(Expert Opin Ther Pat. 2019 Feb; 29(2): 97-114.)(Annals of Oncology(2020)31(suppl_4): S462-S504.10.1016 / annonc / annonc271)(Annals of Oncology(2019)30(suppl_5): v159-v193.10.1093 / annonc / mdz244).
[0005] In 2016, a paper published in Science revealed that MTAP deficiency and PRMT5 are synthetically lethal (Science. 2016 Mar 11;351(6278):1214-8). MTAP is highly deficient in various solid tumors, including pancreatic cancer and glioma. MTAP is an intracellular MTA-degrading enzyme. MTAP deficiency leads to the intracellular accumulation of MTA, which competes with the methylation donor SAM, a functional substrate of PRMT5, for binding to PRMT5, thereby inhibiting PRMT5 function. Since MTA accumulates specifically in MTAP-deficient tumor cells, by strengthening the binding inhibition of MTA and PRMT5, it is possible to achieve specific inhibition of PRMT5 activity in tumor cells, while having a weak inhibitory effect on PRMT5 activity in normal cells, thereby providing a therapeutic safety window, while ensuring anti-tumor efficacy while reducing toxicity (Nat Rev Drug Discov. 2020 Jan; 19(1): 23-38)(Cell Rep. 2016 Apr 19; 15(3): 574-587). Currently, MTA-synergistic PRMT5 inhibitors have obtained preclinical validation data (J Med Chem. 2022 Feb 10; 65(3): 1749-1766). The research and development of MTA-synergistic PRMT5 inhibitors has great potential in the treatment of MTAP-deficient tumors.
[0006] Despite the progress made in PRMT5 research, there is still a lack of effective and selective PRMT5-MTA inhibitors.
[0007] Summary of the Invention
[0008] A compound of formula (I), or a pharmaceutically acceptable salt, isotopic variant, tautomer or stereoisomer thereof:
[0009] in,
[0010] X1, X2 and X3 are each independently selected from -CH=, -O-, -S-, -N= or -NH-, and at least one of X1, X2 and X3 is -N= or -NH-, and a circle indicates aromaticity;
[0011] R1 is selected from C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 3-6 Cycloalkyl or C 1-6 alkyl halide;
[0012] R2 is selected from H, C 1-6 Alkyl or halogen;
[0013] R3 and R4 are independently selected from H, C 1-6 Alkyl, C 3-6 Cycloalkyl or 4-10 membered heterocyclic group, wherein C in R3 or R4 is 1-6 Alkyl, C 3- 6-membered cycloalkyl or 4-10-membered heterocyclyl are each optionally substituted by 1 or 2 R5, wherein R5 is selected from hydrogen, deuterium, halogen, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl, CN, SF5, C 3-6 Cycloalkyl, -S(O)2CF3, -OCF3, -SCF3, -SCH3 or 5-10 membered heteroaryl; said 5-10 membered heteroaryl is optionally further substituted by R6, wherein R6 is selected from H, CN, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, SF5, OR a or 5-6 membered heteroaryl, wherein the 5-6 membered heteroaryl is optionally substituted by 1, 2 or 3 R z replace;
[0014] Alternatively, R3, R4 and the nitrogen atom to which they are attached together form a 4-10 membered heterocyclic group containing 0 or 1 additional heteroatom selected from oxygen, nitrogen or sulfur, and the 4-10 membered heterocyclic group is optionally replaced by 1, 2, 3 or 4 R x replace;
[0015] R x Selected from C 1-6 Alkyl, C1-6 Haloalkyl, phenyl or 5-10 membered heteroaryl, wherein the phenyl or 5-10 membered heteroaryl is optionally substituted by 1, 2 or 3 R y replace;
[0016] R y Selected from halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, SF5, CN, OR a 、C 1-6 Alkoxy, -NR z1 R z2 NR z1 R z2 -C 1-6 Alkyl-, C 3-6 Cycloalkyl, 4-12 membered heterocyclyl or 5-10 membered heteroaryl, wherein the 4-12 membered heterocyclyl or 5-10 membered heteroaryl is optionally substituted by 1, 2 or 3 R z replace;
[0017] R z Selected from C 1-6 Alkyl, halogen, CN, C 1-6 Haloalkyl or C 1-6 alkoxy;
[0018] R a Selected from H, C 1-6 Alkyl or C 1-6 alkyl halide;
[0019] R z1 and R z2 Each independently selected from H or C 1-6 Alkyl; and
[0020] n is 0, 1 or 2.
[0021] In another aspect, the present invention provides a compound of formula (II a ) or formula (II b ) compound, or a pharmaceutically acceptable salt, isotopic variant, tautomer or stereoisomer thereof:
[0022] in,
[0023] R1 is selected from H, C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 3-6 Cycloalkyl or C 1-6 alkyl halide;
[0024] R2 is selected from H, C 1-6 Alkyl or halogen;
[0025] R3 and R4 are independently selected from H, C 1-6 Alkyl, C 3-6 Cycloalkyl or 4-10 membered heterocyclic group, wherein C in R3 or R4 is 1-6 Alkyl, C 3- 6-membered cycloalkyl or 4-10-membered heterocyclyl are each optionally substituted by 1 or 2 R5, wherein R5 is selected from hydrogen, deuterium, halogen, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl, CN, SF5, C 3-6 Cycloalkyl, -S(O)2CF3, -OCF3, -SCF3, -SCH3 or 5-10 membered heteroaryl; said 5-10 membered heteroaryl is optionally further substituted by R6, wherein R6 is selected from H, CN, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, SF5, OR a or 5-6 membered heteroaryl, wherein the 5-6 membered heteroaryl is optionally substituted by 1, 2 or 3 R z replace;
[0026] Alternatively, R3, R4 and the nitrogen atom to which they are attached together form a 4-10 membered heterocyclic group containing 0 or 1 additional heteroatom selected from oxygen, nitrogen or sulfur, and the 4-10 membered heterocyclic group is optionally replaced by 1, 2, 3 or 4 R x replace;
[0027] R x Selected from C 1-6 Alkyl, C 1-6 Haloalkyl, phenyl or 5-10 membered heteroaryl, wherein the phenyl or 5-10 membered heteroaryl is optionally substituted by 1, 2 or 3 R y replace;
[0028] R y Selected from halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, SF5, CN, OR a 、C 1-6 Alkoxy, -NR z1 R z2 NR z1 R z2 -C 1-6 Alkyl-, C 3-6 Cycloalkyl, 4-12 membered heterocyclyl or 5-10 membered heteroaryl, wherein the 4-12 membered heterocyclyl or 5-10 membered heteroaryl is optionally substituted by 1, 2 or 3 R z replace;
[0029] R z Selected from C 1-6Alkyl, halogen, CN, C 1-6 Haloalkyl or C 1-6 alkoxy;
[0030] R a Selected from H, C 1-6 Alkyl or C 1-6 haloalkyl; and
[0031] R z1 and R z2 Each independently selected from H or C 1-6 alkyl.
[0032] In another aspect, the present invention provides specific compounds as exemplified herein.
[0033] In another aspect, the present invention provides a pharmaceutical composition comprising a compound of the present invention and a pharmaceutically acceptable excipient, and further comprising another therapeutic agent.
[0034] In another aspect, the present invention provides use of the compound of the present invention in the preparation of a medicament for treating and / or preventing a disease mediated by PRMT5 methyltransferase.
[0035] In another aspect, the present invention provides a method for treating and / or preventing a PRMT5 methyltransferase-mediated disease in a subject, comprising administering to the subject a compound or composition of the present invention.
[0036] In another aspect, the present invention provides a compound of the present invention or a composition of the present invention for use in treating and / or preventing a disease mediated by PRMT5 methyltransferase.
[0037] In a specific embodiment, the diseases treated by the present invention include cancers selected from the group consisting of acoustic neuroma, adenocarcinoma, adrenal cancer, anal cancer, angiosarcoma (e.g., lymphangiosarcoma, lymphangioendothelioma, hemangioma), appendix cancer, benign monoclonal gamma disease, bile duct cancer, bladder cancer, brain cancer (e.g., meningioma, glioma, e.g., astrocytoma, oligodendroglioma, medulloblastoma), bronchogenic carcinoma, carcinoid tumor, cervical cancer (e.g., cervical adenocarcinoma), choriocarcinoma, chordoma, craniopharyngioma, colorectal cancer (e.g., colon cancer, rectal cancer, large intestinal adenocarcinoma), epithelial cancer, ependymoma, endothelial sarcoma (e.g., Kaposi's sarcoma), cerebrospinal fluid (e.g., glioma ...cerebrospinal fluid (e.g., glioma, astrocytoma, oligodendroglioma, medulloblastoma), cerebrospinal fluid (e.g., glioma, astrocytoma, oligodendroglioma, sarcoma, multiple idiopathic hemorrhagic sarcoma), endometrial cancer (e.g., uterine cancer, uterine sarcoma), esophageal cancer (e.g., esophageal adenocarcinoma, Barrett's gland carcinoma), Ewing's sarcoma, eye cancer (e.g., intraocular melanoma, retinoblastoma), hypereosinophilia, gallbladder cancer, stomach cancer (e.g., gastric adenocarcinoma), gastrointestinal stromal tumor (GIST), head and neck cancer (e.g., head and neck squamous cell carcinoma), oral cancer (e.g., oral squamous cell carcinoma), laryngeal cancer (e.g., laryngeal cancer, pharyngeal cancer, nasopharyngeal cancer, oropharyngeal cancer)), hematopoietic cancer (e.g., leukemia, such as acute lymphoblastic leukemia (ALL) (e.g., B-cell ALL, T-cell ALL), Acute myeloid leukemia (AML) (e.g., B-cell AML, T-cell AML), chronic myeloid leukemia (CML) (e.g., B-cell CML, T-cell CML), chronic lymphocytic leukemia (CLL) (e.g., B-cell CLL, T-cell CLL), follicular lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), marginal zone B-cell lymphoma (e.g., mucosa-associated lymphoid tissue (MALT) lymphoma, nodal marginal zone B-cell lymphoma, splenic marginal zone B-cell lymphoma), primary mediastinal B-cell lymphoma, Burkitt lymphoma, lymphoma Plasma cell lymphoma, hairy cell leukemia (HCL), immunoblastic large cell lymphoma, precursor B lymphoblastic lymphoma, and primary central nervous system (CNS) lymphoma; and T-cell non-Hodgkin lymphoma, such as precursor T-lymphoblastic lymphoma / leukemia, peripheral T-cell lymphoma (such as cutaneous T-cell lymphoma (e.g., mycosis fungoides, Sézary syndrome), angioimmunoblastic T-cell lymphoma, extranodal natural killer T-cell lymphoma, enteropathy-type T-cell lymphoma, subcutaneous panniculitis-like T-cell lymphoma, anaplastic large cell lymphoma); mixtures of one or more of the above leukemias / lymphomas;Multiple myeloma (MM), heavy chain diseases (e.g., alpha chain disease, gamma chain disease, mu chain disease), hemangioblastoma, inflammatory myofibroblastic tumor, immune cell amyloidosis, kidney cancer (e.g., Wilms tumor, renal cell carcinoma), liver cancer (e.g., hepatocellular carcinoma, malignant hepatocellular carcinoma), lung cancer (e.g., bronchogenic carcinoma, small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), lung adenocarcinoma, leiomyosarcoma (LMS), mastocytosis (e.g., systemic mastocytosis), myelodysplastic syndrome (MDS), mesothelioma, myeloproliferative disorders (MPD) (e.g., true Polycythemia vera (PV), essential thrombocythemia (ET), idiopathic myeloid metaplasia (AMM), chronic idiopathic myelofibrosis, chronic myeloid leukemia (CML), chronic neutrophilic leukemia (CNL), hypereosinophilic syndrome (HES), neuroblastoma, neurofibromas (such as neurofibromatosis type 1 or type 2, schwannomatosis), neuroendocrine cancers (such as gastroenteropancreatic neuroendocrine tumors (GEP-NET), carcinoid tumors), osteosarcoma, ovarian cancer (such as cystadenocarcinoma, ovarian embryonal carcinoma, ovarian adenocarcinoma), papillary adenocarcinoma, or penile cancer.
[0038] Other objects and advantages of the present invention will be apparent to those skilled in the art from the following detailed description, examples and claims.
[0039] definition
[0040] Chemical definition
[0041] Definitions of specific functional groups and chemical terms are described in more detail below.
[0042] When a numerical range is listed, it is intended to include every value and sub-range within the stated range. For example, "C 1-6 "Alkyl" includes C1, C2, C3, C4, C5, C6, C 1-6 、C 1-5 、C 1-4 、C 1-3 、C 1-2 、C 2-6 、C 2-5 、C 2-4 、C 2-3 、C 3-6 、C 3-5 、C 3-4 、C 4-6 、C 4-5 and C 5-6 alkyl.
[0043] “C 1-6 "Alkyl" refers to a straight or branched chain saturated hydrocarbon group having 1 to 6 carbon atoms. In some embodiments, C 1-4 Alkyl and C1-2 Alkyl groups are preferred. 1-6 Examples of alkyl groups include: methyl (C1), ethyl (C2), n-propyl (C3), isopropyl (C3), n-butyl (C4), tert-butyl (C4), sec-butyl (C4), isobutyl (C4), n-pentyl (C5), 3-pentyl (C5), pentyl (C5), neopentyl (C5), 3-methyl-2-butyl (C5), tert-pentyl (C5), and n-hexyl (C6). The term “C 1-6 "Alkyl" also includes heteroalkyl groups in which one or more (e.g., 1, 2, 3, or 4) carbon atoms are replaced by heteroatoms (e.g., oxygen, sulfur, nitrogen, boron, silicon, phosphorus). The alkyl group may be optionally substituted with one or more substituents, for example, 1 to 5 substituents, 1 to 3 substituents, or 1 substituent. Conventional alkyl abbreviations include: Me(-CH3), Et(-CH2CH3), iPr(-CH(CH3)2), nPr(-CH2CH2CH3), n-Bu(-CH2CH2CH2CH3), or i-Bu(-CH2CH(CH3)2).
[0044] “C 2-6 "Alkenyl" refers to a straight or branched chain hydrocarbon group having 2 to 6 carbon atoms and at least one carbon-carbon double bond. In some embodiments, C 2-4 Alkenyl is preferred. 2-6 Examples of alkenyl groups include ethenyl (C2), 1-propenyl (C3), 2-propenyl (C3), 1-butenyl (C4), 2-butenyl (C4), butadienyl (C4), pentenyl (C5), pentadienyl (C5), hexenyl (C6), and the like. The term "C 2-6 "Alkenyl" also includes heteroalkenyl groups in which one or more (e.g., 1, 2, 3, or 4) carbon atoms are replaced by heteroatoms (e.g., oxygen, sulfur, nitrogen, boron, silicon, phosphorus). An alkenyl group may be optionally substituted with one or more substituents, for example, with 1 to 5 substituents, 1 to 3 substituents, or 1 substituent.
[0045] “C 2-6 "Alkynyl" refers to a straight or branched chain hydrocarbon group having 2 to 6 carbon atoms, at least one carbon-carbon triple bond, and optionally one or more carbon-carbon double bonds. In some embodiments, C 2-4 Alkynyl is preferred. 2-6 Examples of alkynyl groups include, but are not limited to, ethynyl (C2), 1-propynyl (C3), 2-propynyl (C3), 1-butynyl (C4), 2-butynyl (C4), pentynyl (C5), hexynyl (C6), and the like. The term "C 2-6"Alkynyl" also includes heteroalkynyl groups in which one or more (e.g., 1, 2, 3, or 4) carbon atoms are replaced by heteroatoms (e.g., oxygen, sulfur, nitrogen, boron, silicon, phosphorus). Alkynyl groups can be optionally substituted with one or more substituents, for example, 1 to 5 substituents, 1 to 3 substituents, or 1 substituent.
[0046] “C 1-6 "Alkylene" refers to the removal of C 1-6 In some embodiments, C 1-4 Alkylene, C 2-4 Alkylene and C 1-3 Alkylene is preferred. Unsubstituted alkylene includes, but is not limited to, methylene (-CH2-), ethylene (-CH2CH2-), propylene (-CH2CH2CH2-), butylene (-CH2CH2CH2CH2-), pentylene (-CH2CH2CH2CH2CH2-), hexylene (-CH2CH2CH2CH2CH2CH2-), and the like. Exemplary substituted alkylenes, for example, alkylenes substituted with one or more alkyl (methyl) groups, include, but are not limited to, substituted methylene (-CH(CH3)-, -C(CH3)2-), substituted ethylene (-CH(CH3)CH2-, -CH2CH(CH3)-, -C(CH3)2CH2-, -CH2C(CH3) 2- ), substituted propylene (-CH(CH3)CH2CH2-, -CH2CH(CH3)CH2-, -CH2CH2CH(CH3)-, -C(CH3)2CH2CH2-, -CH2C(CH3)2CH2-, -CH2CH2C(CH3)2-), and the like.
[0047] “C 2-6 "Alkenylene" refers to the removal of C 2-6 In some embodiments, C 2-4Alkenylene is particularly preferred. Exemplary unsubstituted alkenylene groups include, but are not limited to, vinylene (-CH=CH-) and propenylene (e.g., -CH=CHCH2-, -CH2-CH=CH-). Exemplary substituted alkenylene groups, for example, alkenylene groups substituted with one or more alkyl (methyl) groups, include, but are not limited to, substituted ethylene (-C(CH3)=CH-, -CH=C(CH3)-), substituted propenylene (-C(CH3)=CHCH2-, -CH=C(CH3)CH2-, -CH=CHCH(CH3)-, -CH=CHC(CH3)2-, -CH(CH3)-CH=CH-, -C(CH3)2-CH=CH-, -CH2-C(CH3)=CH-, -CH2-CH=C(CH3)-), and the like.
[0048] “C 2-6 "Alkynylidene" refers to the removal of C 2-6 In some embodiments, C 2-4 Alkyne is particularly preferred. Exemplary alkynyl includes, but is not limited to, ethynyl (-C≡C-), substituted or unsubstituted propynyl (-C≡CCH2-), and the like.
[0049] "Halo" or "halogen" refers to fluorine (F), chlorine (Cl), bromine (Br) and iodine (I).
[0050] Therefore, “C 1-6 "Haloalkyl" refers to the above-mentioned "C 1-6 Alkyl", which is substituted by one or more halogen groups. In some embodiments, C 1-4 Halogenated alkyl is particularly preferred, more preferably C 1-2 Haloalkyl. Exemplary haloalkyl groups include, but are not limited to, -CF3, -CH2F, -CHF2, -CHFCH2F, -CH2CHF2, -CF2CF3, -CCl3, -CH2Cl, -CHCl2, 2,2,2-trifluoro-1,1-dimethyl-ethyl, and the like. The haloalkyl group can be substituted at any available point of attachment, for example, with 1 to 5 substituents, 1 to 3 substituents, or 1 substituent.
[0051] “C 1-6 "Alkoxy" refers to an -OR group, wherein R is a C 1-6 Alkyl. C 1-4 Alkoxy groups are preferred.
[0052] “C 1-6 "Haloalkoxy" refers to "C 1-6Alkoxy", which is substituted by one or more halogen groups. In some embodiments, C 1-4 Halogenated alkoxyalkyl is particularly preferred, more preferably C 1-2 Halogenated alkoxyalkyl.
[0053] “C 3-10 "Cycloalkyl" refers to a non-aromatic cyclic hydrocarbon group having 3 to 10 ring carbon atoms and zero heteroatoms. In some embodiments, C 4-10 Cycloalkyl, C 5-10 Cycloalkyl, C 4-7 Cycloalkyl, C 3-7 Cycloalkyl, C 3-6 Cycloalkyl, C 3-5 Cycloalkyl and C 3-4 Cycloalkyl is particularly preferred, more preferably C 5-6 Cycloalkyl. Cycloalkyl also includes a ring system in which the above-mentioned cycloalkyl ring is fused to one or more aryl or heteroaryl groups, wherein the point of attachment is on the cycloalkyl ring, and in such a case, the number of carbons continues to represent the number of carbons in the cycloalkyl system. Exemplary cycloalkyls include, but are not limited to, cyclopropyl (C3), cyclopropenyl (C3), cyclobutyl (C4), cyclobutenyl (C4), cyclopentyl (C5), cyclopentenyl (C5), cyclohexyl (C6), cyclohexenyl (C6), cyclohexadienyl (C6), cycloheptyl (C7), cycloheptenyl (C7), cycloheptadienyl (C7), cycloheptatrienyl (C7), and the like. The cycloalkyl group may be optionally substituted with one or more substituents, for example, with 1 to 5 substituents, 1 to 3 substituents, or 1 substituent.
[0054] "3-12 membered heterocyclyl" refers to a group of a 3- to 12-membered non-aromatic ring system having ring carbon atoms and 1 to 5 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, sulfur, boron, phosphorus, and silicon. In heterocyclyl groups containing one or more nitrogen atoms, the point of attachment may be a carbon or nitrogen atom, as valence permits. In some embodiments, 3-10 membered heterocyclyl is preferably a 3-10 membered non-aromatic ring system having ring carbon atoms and 1 to 3 ring heteroatoms; in some embodiments, 4-10 membered heterocyclyl is preferably a 4-10 membered non-aromatic ring system having ring carbon atoms and 1 to 4 ring heteroatoms; in some embodiments, 5-10 membered heterocyclyl is preferably a 5-10 membered non-aromatic ring system having ring carbon atoms and 1 to 5 ring heteroatoms; in some embodiments, 5-8 membered heterocyclyl is preferably a 5-8 membered non-aromatic ring system having ring carbon atoms and 1 to 5 ring heteroatoms; in some embodiments, 3-7 membered heterocyclyl is preferably a A 3- to 7-membered non-aromatic ring system having ring carbon atoms and 1 to 4 ring heteroatoms; preferably a 3- to 6-membered heterocyclyl, which is a 3- to 6-membered non-aromatic ring system having ring carbon atoms and 1 to 3 ring heteroatoms; preferably a 4- to 7-membered heterocyclyl, which is a 4- to 7-membered non-aromatic ring system having ring carbon atoms and 1 to 3 ring heteroatoms; preferably a 4- to 6-membered heterocyclyl, which is a 4- to 6-membered non-aromatic ring system having ring carbon atoms and 1 to 3 ring heteroatoms; more preferably a 5- to 6-membered heterocyclyl, which is a 5- to 6-membered non-aromatic ring system having ring carbon atoms and 1 to 3 ring heteroatoms; more preferably a 3- to 5-membered heterocyclyl, which is a 3- to 5-membered non-aromatic ring system having ring carbon atoms and 1 to 3 ring heteroatoms. Heterocyclyl also includes a ring system in which the above-mentioned heterocyclyl ring is fused to one or more cycloalkyl groups, wherein the point of attachment is on the cycloalkyl ring, or a ring system in which the above-mentioned heterocyclyl ring is fused to one or more aryl or heteroaryl groups, wherein the point of attachment is on the heterocyclyl ring; and in such a case, the number of ring members continues to represent the number of ring members in the heterocyclyl ring system. Exemplary 3-membered heterocyclyls containing one heteroatom include, but are not limited to, aziridine, oxirane, and thiorenyl. Exemplary 4-membered heterocyclyls containing one heteroatom include, but are not limited to, azetidinyl, oxetane, and thiidine. Exemplary 5-membered heterocyclyls containing one heteroatom include, but are not limited to, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothienyl, dihydrothienyl, pyrrolidinyl, dihydropyrrolyl, and pyrrolyl-2,5-dione. Exemplary 5-membered heterocyclic groups containing two heteroatoms include, but are not limited to, dioxolane, oxasulfuranyl, disulfuranyl, and oxazolidin-2-one. Exemplary 5-membered heterocyclic groups containing three heteroatoms include, but are not limited to, triazolinyl, oxadiazolinyl, and thiadiazolinyl.Exemplary 6-membered heterocyclyls containing one heteroatom include, but are not limited to, piperidinyl, tetrahydropyranyl, dihydropyridinyl, and thianyl. Exemplary 6-membered heterocyclyls containing two heteroatoms include, but are not limited to, piperazinyl, morpholinyl, dithianyl, and dioxanyl. Exemplary 6-membered heterocyclyls containing three heteroatoms include, but are not limited to, hexahydrotriazinyl. Exemplary 7-membered heterocyclyls containing one heteroatom include, but are not limited to, azepanyl, oxepanyl, and thienyl. Exemplary 5-membered heterocyclyls fused to a C6 aryl ring (also referred to herein as 5,6-bicyclic heterocyclyls) include, but are not limited to, dihydroindolinyl, isoindolinyl, dihydrobenzofuranyl, dihydrobenzothiophenyl, benzoxazolinone, and the like. Exemplary 6-membered heterocyclyl groups fused to a C6 aryl ring (also referred to herein as 6,6-bicyclic heterocyclyl groups) include, but are not limited to, tetrahydroquinolinyl, tetrahydroisoquinolinyl, tetrahydrobenzopyranyl, tetrahydropyranopyridinyl, and the like. The heterocyclyl group may be optionally substituted with one or more substituents, for example, 1 to 5 substituents, 1 to 3 substituents, or 1 substituent.
[0055] “C 6-10 "Aryl" refers to a monocyclic or polycyclic (e.g., bicyclic) 4n+2 aromatic ring system (e.g., having 6 or 10 π electrons shared in a cyclic arrangement) having 6-10 ring carbon atoms and zero heteroatoms. In some embodiments, an aryl group has six ring carbon atoms ("C6 aryl"; e.g., phenyl). In some embodiments, an aryl group has ten ring carbon atoms ("C 10 Aryl also includes ring systems in which an aryl ring as described above is fused to one or more cycloalkyl or heterocyclyl groups, and the point of attachment is on the aryl ring, in which case the number of carbon atoms continues to refer to the number of carbon atoms in the aryl ring system. Aryl groups can be optionally substituted with one or more substituents, for example, with 1 to 5 substituents, 1 to 3 substituents, or 1 substituent.
[0056] "5-14 membered heteroaryl" refers to a group of a 5-14 membered monocyclic or bicyclic 4n+2 aromatic ring system (e.g., having 6, 10, or 14 π electrons shared in a cyclic arrangement) having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur. In heteroaryl groups containing one or more nitrogen atoms, the point of attachment may be a carbon or nitrogen atom as long as valence permits. Heteroaryl bicyclic ring systems may include one or more heteroatoms in one or both rings. Heteroaryl also includes ring systems in which the above-mentioned heteroaryl rings are fused to one or more cycloalkyl or heterocyclyl groups, and the point of attachment is on the heteroaryl ring, in which case the number of carbon atoms continues to represent the number of carbon atoms in the heteroaryl ring system. In some embodiments, 5-10 membered heteroaryl is preferred, which is a 5-10 membered monocyclic or bicyclic 4n+2 aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms. In some embodiments, 5-10 membered heteroaryls are preferred, which are 6-10 membered monocyclic or bicyclic 4n+2 aromatic ring systems having ring carbon atoms and 1-4 ring heteroatoms. In some embodiments, 5-9 membered heteroaryls are preferred, which are 5-9 membered monocyclic or bicyclic 4n+2 aromatic ring systems having ring carbon atoms and 1-4 ring heteroatoms. In other embodiments, 5-6 membered heteroaryls are particularly preferred, which are 5-6 membered monocyclic or bicyclic 4n+2 aromatic ring systems having ring carbon atoms and 1-4 ring heteroatoms. Exemplary 5-membered heteroaryls containing one heteroatom include, but are not limited to, pyrrolyl, furanyl, and thienyl. Exemplary 5-membered heteroaryls containing two heteroatoms include, but are not limited to, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, and isothiazolyl. Exemplary 5-membered heteroaryl groups containing three heteroatoms include, but are not limited to, triazolyl, oxadiazolyl (e.g., 1,2,4-oxadiazolyl), and thiadiazolyl. Exemplary 5-membered heteroaryl groups containing four heteroatoms include, but are not limited to, tetrazolyl. Exemplary 6-membered heteroaryl groups containing one heteroatom include, but are not limited to, pyridinyl. Exemplary 6-membered heteroaryl groups containing two heteroatoms include, but are not limited to, pyridazinyl, pyrimidinyl, and pyrazinyl. Exemplary 6-membered heteroaryl groups containing three or four heteroatoms include, but are not limited to, triazinyl and tetrazinyl, respectively. Exemplary 7-membered heteroaryl groups containing one heteroatom include, but are not limited to, azacycloheptatrienyl, oxacycloheptatrienyl, and thiacycloheptatrienyl. Exemplary 5,6-bicyclic heteroaryl groups include, but are not limited to, indolyl, isoindolyl, indazolyl, benzotriazolyl, benzothiophenyl, isobenzothiophenyl, benzofuranyl, benzisofuranyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzoxadiazolyl, benzothiazolyl, benzisothiazolyl, benzothiadiazolyl, indanyl, and purinyl. Exemplary 6,6-bicyclic heteroaryl groups include, but are not limited to, naphthyridinyl, pteridinyl, quinolinyl, isoquinolinyl, cinnolinyl, quinoxalinyl, phthalazinyl, and quinazolinyl.A heteroaryl group can be optionally substituted with one or more substituents, for example, with 1 to 5 substituents, 1 to 3 substituents, or 1 substituent.
[0057] "Cycloalkylene", "heterocyclylene", "arylene" or "heteroarylene" is a divalent group formed by removing another hydrogen from the above-defined "cycloalkyl", "heterocyclyl", "aryl" or "heteroaryl", and may be substituted or unsubstituted. For example, "C 5-7 "Cycloalkylene" refers to the removal of C 5-7 The "5-8 membered heterocyclylene" refers to a divalent group formed by removing another hydrogen atom of a 5-8 membered heterocyclyl. The "C 6-10 "Arylene" refers to the removal of C 6-10 The "5- to 6-membered heteroarylene group" refers to a divalent group formed by removing another hydrogen atom of a 5- to 6-membered heteroaryl group.
[0058] Alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, and the like are defined herein as optionally substituted groups.
[0059] Exemplary substituents on carbon atoms include, but are not limited to, halogen, -CN, -NO2, -N3, -SO2H, -SO3H, -OH, -OR aa 、-ON(R bb )2、-N(R bb )2、-N(R bb )3 + X - 、-N(OR cc )R bb 、-SH、-SR aa 、-SSR cc 、-C(=O)R aa 、-CO2H、-CHO、-C(OR cc )2, -CO2R aa 、-OC(=O)R aa 、-OCO2R aa 、-C(=O)N(R bb )2、-OC(=O)N(R bb )2、-NR bb C(=O)R aa 、-NR bb CO2R aa 、-NR bb C(=O)N(R bb )2、-C(=NR bb )R aa 、-C(=NR bb )OR aa、-OC(=NR bb )R aa 、-OC(=NR bb )OR aa 、-C(=NR bb )N(R bb )2、-OC(=NR bb )N(R bb )2、-NR bb C(=NR bb )N(R bb )2、-C(=O)NR bb SO2R aa 、-NR bb SO2R aa 、-SO2N(R bb )2、-SO2R aa 、-SO2OR aa 、-OSO2R aa 、-S(=O)R aa 、-OS(=O)R aa 、-Si(R aa )3、-OSi(R aa )3、-C(=S)N(R bb )2、-C(=O)SR aa 、-C(=S)SR aa 、-SC(=S)SR aa 、-SC(=O)SR aa 、-OC(=O)SR aa 、-SC(=O)OR aa 、-SC(=O)R aa 、-P(=O)2R aa 、-OP(=O)2R aa 、-P(=O)(R aa )2、-OP(=O)(R aa )2、-OP(=O)(OR cc )2、-P(=O)2N(R bb )2、-OP(=O)2N(R bb )2、-P(=O)(NR bb )2、-OP(=O)(NR bb )2、-NR bb P(=O)(OR cc )2、-NR bb P(=O)(NR bb )2、-P(R cc )2、-P(R cc )3、-OP(R cc )2、-OP(Rcc )3、-B(R aa )2、-B(OR cc )2, -BR aa (OR cc ), alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl is independently replaced by 0, 1, 2, 3, 4 or 5 R dd group substitution;
[0060] Or the two geminal hydrogen atoms on the carbon atom are replaced by groups =O, =S, =NN(R bb )2, =NNR bb C(=O)R aa 、=NNR bb C(=O)OR aa 、=NNR bb S(=O)2R aa 、=NR bb or = NOR cc replace;
[0061] R aa Each of R is independently selected from alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, or two R aa The groups are combined to form a heterocyclyl or heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl group is independently replaced by 0, 1, 2, 3, 4 or 5 R dd group substitution;
[0062] R bb Each of the following is independently selected from: hydrogen, -OH, -OR aa 、-N(R cc )2, -CN, -C(=O)R aa 、-C(=O)N(R cc )2, -CO2R aa 、-SO2R aa 、-C(=NR cc )OR aa 、-C(=NR cc )N(R cc )2、-SO2N(R cc )2, -SO2R cc 、-SO2OR cc 、-SOR aa 、-C(=S)N(R cc )2, -C(=O)SR cc 、-C(=S)SR cc 、-P(=O)2R aa、-P(=O)(R aa )2、-P(=O)2N(R cc )2、-P(=O)(NR cc )2, alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, or two R bb The groups are combined to form a heterocyclyl or heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl group is independently replaced by 0, 1, 2, 3, 4 or 5 R dd group substitution;
[0063] R cc Each of R is independently selected from hydrogen, alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, or two R cc The groups are combined to form a heterocyclyl or heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl group is independently replaced by 0, 1, 2, 3, 4 or 5 R dd group substitution;
[0064] R dd Each of the is independently selected from: halogen, -CN, -NO2, -N3, -SO2H, -SO3H, -OH, -OR ee 、-ON(R ff )2、-N(R ff )2,、-N(R ff )3 + X - 、-N(OR ee )R ff 、-SH、-SR ee 、-SSR ee 、-C(=O)R ee 、-CO2H、-CO2R ee 、-OC(=O)R ee 、-OCO2R ee 、-C(=O)N(R ff )2、-OC(=O)N(R ff )2、-NR ff C(=O)R ee 、-NR ff CO2R ee 、-NR ff C(=O)N(R ff )2、-C(=NR ff )OR ee 、-OC(=NR ff )R ee 、-OC(=NR ff )OR ee、-C(=NR ff )N(R ff )2、-OC(=NR ff )N(R ff )2、-NR ff C(=NR ff )N(R ff )2、-NR ff SO2R ee 、-SO2N(R ff )2, -SO2R ee 、-SO2OR ee 、-OSO2R ee 、-S(=O)R ee 、-Si(R ee )3、-OSi(R ee )3、-C(=S)N(R ff )2, -C(=O)SR ee 、-C(=S)SR ee 、-SC(=S)SR ee 、-P(=O)2R ee 、-P(=O)(R ee )2、-OP(=O)(R ee )2、-OP(=O)(OR ee )2, alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl is independently substituted by 0, 1, 2, 3, 4 or 5 R gg Group substitution, or two geminal R dd Substituents may combine to form =O or =S;
[0065] R ee Each of R is independently selected from alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl and heteroaryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl is independently replaced by 0, 1, 2, 3, 4 or 5 R gg group substitution;
[0066] R ff Each of R is independently selected from hydrogen, alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, or two R ff The groups are combined to form a heterocyclic or heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl and heteroaryl group is independently replaced by 0, 1, 2, 3, 4 or 5 R gg group substitution;
[0067] R ggEach of the independently: halogen, -CN, -NO2, -N3, -SO2H, -SO3H, -OH, -OC 1-6 Alkyl, -ON(C 1-6 Alkyl)2, -N(C 1-6 Alkyl)2, -N(C 1-6 Alkyl)3 + X - 、-NH(C 1-6 Alkyl)2 + X - 、-NH2(C 1-6 alkyl) + X - 、-NH3 + X - 、-N(OC 1-6 Alkyl)(C 1-6 Alkyl), -N(OH)(C 1-6 Alkyl), -NH(OH), -SH, -SC 1-6 Alkyl, -SS(C 1-6 alkyl), -C(=O)(C 1-6 alkyl), -CO2H, -CO2(C 1-6 alkyl), -OC(=O)(C 1-6 Alkyl), -OCO2(C 1-6 alkyl), -C(=O)NH2, -C(=O)N(C 1-6 alkyl)2, -OC(=O)NH(C 1-6 alkyl), -NHC(=O)(C 1-6 Alkyl), -N(C 1-6 alkyl)C(=O)(C 1-6 Alkyl), -NHCO2(C 1-6 alkyl), -NHC(=O)N(C 1-6 Alkyl)2, -NHC(=O)NH(C 1-6 alkyl), -NHC(=O)NH2, -C(=NH)O(C 1-6 alkyl), -OC(=NH)(C 1-6 alkyl), -OC(=NH)OC 1-6 Alkyl, -C(=NH)N(C 1-6 Alkyl)2, -C(=NH)NH(C 1-6 alkyl), -C(=NH)NH2, -OC(=NH)N(C 1-6 Alkyl)2, -OC(NH)NH(C 1-6 alkyl), -OC(NH)NH2, -NHC(NH)N(C 1-6Alkyl)2, -NHC(=NH)NH2, -NHSO2(C 1-6 Alkyl), -SO2N(C 1-6 Alkyl)2, -SO2NH(C 1-6 alkyl), -SO2NH2, -SO2C 1- 6-alkyl, -SO2OC 1-6 Alkyl, -OSO2C 1-6 Alkyl, -SOC 1-6 Alkyl, -Si(C 1-6 alkyl)3, -OSi(C 1-6 alkyl)3, -C(=S)N(C 1-6 alkyl)2、C(=S)NH(C 1-6 alkyl), C(=S)NH2, -C(=O)S(C 1-6 alkyl), -C(=S)SC 1-6 Alkyl, -SC(=S)SC 1-6 Alkyl, -P(=O)2(C 1-6 alkyl), -P(=O)(C 1-6 alkyl)2, -OP(=O)(C 1-6 alkyl)2, -OP(=O)(OC 1-6 Alkyl)2, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C7 cycloalkyl, C6-C 10 Aryl, C3-C7 heterocyclic, C5-C 10 heteroaryl; or two geminal R gg Substituents may combine to form =O or =S; wherein X - For the counter ion.
[0068] Exemplary substituents on nitrogen atoms include, but are not limited to, hydrogen, -OH, -OR aa 、-N(R cc )2, -CN, -C(=O)R aa 、-C(=O)N(R cc )2, -CO2R aa 、-SO2R aa 、-C(=NR bb )R aa 、-C(=NR cc )OR aa 、-C(=NR cc )N(R cc )2、-SO2N(R cc )2, -SO2R cc 、-SO2OR cc 、-SORaa 、-C(=S)N(R cc )2, -C(=O)SR cc 、-C(=S)SR cc 、-P(=O)2R aa 、-P(=O)(R aa )2、-P(=O)2N(R cc )2、-P(=O)(NR cc )2, alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, or two R attached to the nitrogen atom cc The groups are combined to form a heterocyclic or heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl and heteroaryl group is independently replaced by 0, 1, 2, 3, 4 or 5 R dd Group substituted, and wherein R aa 、R bb 、R cc and R dd As mentioned above.
[0069] The term "deuterium (D or 2H)" is a stable isotope of hydrogen that occurs at a natural abundance of 0.015 mol%. The term "deuterated" refers to a group or compound in which one or more hydrogen atoms H are replaced by D.
[0070] "Deuterated compound" refers to a compound in which one or more carbon-bonded hydrogen atoms are replaced by one or more deuterium atoms. Similarly, "deuterated" refers to a chemical structure or organic group in which one or more carbon-bonded hydrogen atoms are replaced by one or more deuterium atoms, for example, "deuterated alkyl", "deuterated cycloalkyl", "deuterated heterocycloalkyl", "deuterated aryl", etc. For example, "deuterated alkyl" refers to an alkyl group as defined herein in which at least one carbon-bonded hydrogen atom is replaced by deuterium. In a deuterated alkyl group, at least one carbon atom is bonded to one deuterium; a carbon atom can be bonded to multiple deuterium atoms; and multiple carbon atoms in an alkyl group can also be bonded to deuterium. For example, deuterated methyl includes methyl-d3, in which three hydrogen atoms are replaced by deuterium; monodeuterated methyl and dideuterated methyl are also included. In some embodiments, the compounds of the present invention include deuterated compounds.
[0071] Other definitions
[0072] As used herein, the term "pharmaceutically acceptable salt" refers to those carboxylate salts, amino acid addition salts of the compounds of the present invention that are suitable for use in contact with patient tissues within the scope of sound medical judgment, do not produce undue toxicity, irritation, allergic response, etc., are commensurate with a reasonable benefit / risk ratio, and are effective for their intended use, including (where possible) zwitterionic forms of the compounds of the present invention.
[0073] "Subjects" to be administered include, but are not limited to, humans (i.e., males or females of any age group, e.g., pediatric subjects (e.g., infants, children, adolescents) or adult subjects (e.g., young adults, middle-aged adults, or older adults)) and / or non-human animals, e.g., mammals, e.g., primates (e.g., cynomolgus monkeys, rhesus monkeys), cattle, pigs, horses, sheep, goats, rodents, cats, and / or dogs. In some embodiments, the subject is a human. In some embodiments, the subject is a non-human animal. The terms "human," "patient," and "subject" are used interchangeably herein.
[0074] "Disease," "disorder," and "condition" are used interchangeably herein.
[0075] Generally, an "effective amount" of a compound is an amount sufficient to elicit the desired biological response. As will be appreciated by those skilled in the art, the effective amount of a compound of the invention can vary depending on factors such as the biological target, the pharmacokinetics of the compound, the disease being treated, the mode of administration, and the age, health, and symptoms of the subject. An effective amount includes both a therapeutically effective amount and a prophylactically effective amount.
[0076] "Combination" and related terms refer to the simultaneous or sequential administration of a compound of the invention and other therapeutic agents. For example, a compound of the invention can be administered simultaneously or sequentially with the other therapeutic agents in separate unit dosage forms, or can be administered simultaneously with the other therapeutic agents in a single unit dosage form. Specific implementation plan
[0077] Herein, "compounds of the present invention" refers to the following compounds of formula (I) (including sub-general formulas, such as formula (II) a )、(II b ), (III), (IV), (III-1), (III-2), (III-3), (IV-1), (IV-2), (V-1), (V-2), (VI-1), (VI-2), (VII-1) or (VII-2) etc.), pharmaceutically acceptable salts, enantiomers, diastereomers or isotopic variants thereof, and mixtures thereof.
[0078] In one embodiment, the present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt, isotopic variant, tautomer, or stereoisomer thereof:
[0079] X1, X2 and X3 are each independently selected from CH, O, S or N, and X1, X2 and X3 contain at least one N atom. The circle indicates aromaticity.
[0080] R1 is selected from H, C 1-6 Alkyl, deuterated C 1-6Alkyl, C 3-6 Cycloalkyl or C 1-6 alkyl halide;
[0081] R2 is selected from H, C 1-6 Alkyl or halogen;
[0082] R3 and R4 are independently selected from H, C 1-6 Alkyl, C 3-6 Cycloalkyl or 4-10 membered heterocyclic group, wherein C in R3 or R4 is 1-6 Alkyl, C 3- 6-membered cycloalkyl or 4-10-membered heterocyclyl are each optionally substituted by 1 or 2 R5, wherein R5 is selected from hydrogen, deuterium, halogen, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl, CN, SF5, C 3-6 Cycloalkyl, -S(O)2CF3, -OCF3, -SCF3, -SCH3 or 5-10 membered heteroaryl; said 5-10 membered heteroaryl is optionally further substituted by R6, wherein R6 is selected from H, CN, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, SF5, OR a or 5-6 membered heteroaryl, wherein the 5-6 membered heteroaryl is optionally substituted by 1, 2 or 3 R z replace;
[0083] Alternatively, R3, R4 and the nitrogen atom to which they are attached together form a 4-10 membered heterocyclic group containing 0 or 1 additional heteroatom selected from oxygen, nitrogen or sulfur, and the 4-10 membered heterocyclic group is optionally replaced by 1, 2, 3 or 4 R x replace;
[0084] R x Selected from C 1-6 Alkyl, C 1-6 Haloalkyl, phenyl or 5-10 membered heteroaryl, wherein the phenyl or 5-10 membered heteroaryl is optionally substituted by 1, 2 or 3 R y replace;
[0085] R y Selected from halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, SF5, CN, OR a 、C 1-6 Alkoxy, -NR z1 R z2 NR z1 R z2 -C 1-6 Alkyl-, C 3-6Cycloalkyl, 4-12 membered heterocyclyl or 5-10 membered heteroaryl, wherein the 4-12 membered heterocyclyl or 5-10 membered heteroaryl is optionally substituted by 1, 2 or 3 R z replace;
[0086] R z Selected from C 1-6 Alkyl, halogen, CN, C 1-6 Haloalkyl or C 1-6 alkoxy;
[0087] R a Selected from H, C 1-6 Alkyl or C 1-6 alkyl halide;
[0088] R z1 and R z2 Each independently selected from H or C 1-6 Alkyl; and
[0089] n is 0, 1 or 2.
[0090] In some embodiments, X1, X2 and X3 are each independently selected from -CH=, -O-, -S-, -N= or -NH-, and at least one of X1, X2 and X3 is -N= or -NH-.
[0091] In some embodiments, -NR3R4 is
[0092] In some embodiments, -NR3R4 is
[0093] In some embodiments, -NR3R4 is
[0094] In some embodiments, -NR3R4 is
[0095] In another embodiment, the present invention relates to a a ) or formula (II b ) compound, or a pharmaceutically acceptable salt, isotopic variant, tautomer or stereoisomer thereof:
[0096] in,
[0097] R1 is selected from H, C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 3-6Cycloalkyl or C 1-6 alkyl halide;
[0098] R2 is selected from H, C 1-6 Alkyl or halogen;
[0099] R3 and R4 are independently selected from H, C 1-6 Alkyl, C 3-6 Cycloalkyl or 4-10 membered heterocyclic group, wherein C in R3 or R4 is 1-6 Alkyl, C 3- 6-membered cycloalkyl or 4-10-membered heterocyclyl are each optionally substituted by 1 or 2 R5, wherein R5 is selected from hydrogen, deuterium, halogen, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl, CN, SF5, C 3-6 Cycloalkyl, -S(O)2CF3, -OCF3, -SCF3, -SCH3 or 5-10 membered heteroaryl; said 5-10 membered heteroaryl is optionally further substituted by R6, wherein R6 is selected from H, CN, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, SF5, OR a or 5-6 membered heteroaryl, wherein the 5-6 membered heteroaryl is optionally substituted by 1, 2 or 3 R z replace;
[0100] Alternatively, R3, R4 and the nitrogen atom to which they are attached together form a 4-10 membered heterocyclic group containing 0 or 1 additional heteroatom selected from oxygen, nitrogen or sulfur, and the 4-10 membered heterocyclic group is optionally replaced by 1, 2, 3 or 4 R x replace;
[0101] R x Selected from C 1-6 Alkyl, C 1-6 Haloalkyl, phenyl or 5-10 membered heteroaryl, wherein the phenyl or 5-10 membered heteroaryl is optionally substituted by 1, 2 or 3 R y replace;
[0102] R y Selected from halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, SF5, CN, OR a 、C 1-6 Alkoxy, -NR z1 R z2 NR z1 R z2 -C 1-6 Alkyl-, C 3-6Cycloalkyl, 4-12 membered heterocyclyl or 5-10 membered heteroaryl, wherein the 4-12 membered heterocyclyl or 5-10 membered heteroaryl is optionally substituted by 1, 2 or 3 R z replace;
[0103] R z Selected from C 1-6 Alkyl, halogen, CN, C 1-6 Haloalkyl or C 1-6 alkoxy;
[0104] R a Selected from H, C 1-6 Alkyl or C 1-6 haloalkyl; and
[0105] R z1 and R z2 Each independently selected from H or C 1-6 alkyl.
[0106] In another embodiment, the present invention provides a compound of formula (III) or formula (IV), or a pharmaceutically acceptable salt, isotopic variant, tautomer or stereoisomer thereof:
[0107] R1 is selected from H, C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 3-6 Cycloalkyl or C 1-6 alkyl halide;
[0108] R2 is selected from H, methyl, Cl or F;
[0109] R 5a or R 5b Each is independently selected from 5-10 membered heteroaryl; the 5-10 membered heteroaryl is optionally substituted by R6, R6 is selected from H, CN, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, SF5, OR a or 5-6 membered heteroaryl; said 5-6 membered heteroaryl is optionally substituted by 1, 2 or 3 R z replace;
[0110] R x1 is selected from phenyl or 5-10 membered heteroaryl, wherein the phenyl or 5-10 membered heteroaryl is optionally substituted by 1, 2 or 3 R y replace;
[0111] R y Selected from halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, SF5, CN, OR a 、C 1-6Alkoxy, -NR z1 R z2 NR z1 R z2 -C 1-6 Alkyl-, C 3-6 Cycloalkyl, 4-12 membered heterocyclyl or 5-10 membered heteroaryl, wherein the 4-12 membered heterocyclyl or 5-10 membered heteroaryl is optionally substituted by 1, 2 or 3 R z replace;
[0112] R z Selected from C 1-6 Alkyl, halogen, CN, C 1-6 Haloalkyl or C 1-6 alkoxy;
[0113] R a Selected from H, C 1-6 Alkyl or C 1-6 alkyl halide;
[0114] R x2 Selected from C 1-6 Alkyl or C 1-6 alkyl halide;
[0115] R z1 and R z2 Each independently selected from H or C 1-6 Alkyl; and
[0116] Y is selected from O, S or CH2.
[0117] In another embodiment, the present invention provides a compound of formula (VI) or formula (VII), or a pharmaceutically acceptable salt, isotopic variant, tautomer or stereoisomer thereof:
[0118] R1 is selected from H, C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 3-6 Cycloalkyl or C 1-6 alkyl halide;
[0119] R2 is selected from H, methyl, Cl or F;
[0120] R3 is selected from H, C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 3-6 Cycloalkyl or 4-10 membered heterocyclic group; said C 1-6 Alkyl or 4-10 membered heterocyclyl is optionally substituted with 1 or 2 R5;
[0121] R5 is selected from hydrogen, deuterium, halogen, C 1-6 Alkyl, C 1-6Alkoxy, C 1-6 Halogenated alkyl, C 1-6 Halogenated alkoxy, CN, SF5, C 3-6 Cycloalkyl, -S(O)2CF3, -OCF3, -SCF3, -SCH3 or 5-10 membered heteroaryl; said 5-10 membered heteroaryl is optionally further substituted by R6, R6 is selected from H, CN, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, SF5, OR a or 5-6 membered heteroaryl; said 5-6 membered heteroaryl is optionally substituted by 1, 2 or 3 R z replace;
[0122] R z Selected from C 1-6 Alkyl, halogen, CN, C 1-6 Haloalkyl or C 1-6 alkoxy;
[0123] R a Selected from H, C 1-6 Alkyl or C 1-6 alkyl halide;
[0124] Y is selected from NH, O, S or CH2;
[0125] Z is selected from N or CH.
[0126] In some embodiments, R1 is CH3 or CD3.
[0127] In some embodiments, the compound is
[0128] In some embodiments, the compound is
[0129] In some embodiments, for:
[0130] In another embodiment, the present invention provides a compound of formula (III-1), or a pharmaceutically acceptable salt, isotopic variant, tautomer or stereoisomer thereof:
[0131] R1 is selected from methyl, CD3, ethyl, or cyclopropyl;
[0132] R 5a or R 5b Each is independently selected from 6-membered heteroaryl; the 6-membered heteroaryl is optionally further substituted by R6, R6 is selected from H, CN, halogen, C 1-6 Alkyl, C 1-6Halogenated alkyl, SF5, OR a or 5-6 membered heteroaryl; said 5-6 membered heteroaryl is optionally substituted by 1, 2 or 3 R z replace;
[0133] R z Selected from C 1-6 Alkyl, halogen, CN, C 1-6 Haloalkyl or C 1-6 alkoxy;
[0134] R a Selected from H, C 1-6 Alkyl or C 1-6 Halogenated alkyl.
[0135] In another more specific embodiment, the present invention provides a compound of formula (III-2), or a pharmaceutically acceptable salt, isotopic variant, tautomer or stereoisomer thereof:
[0136] R1 is selected from methyl, CD3, ethyl, or cyclopropyl;
[0137] R 5b for It is optionally further substituted with R6, R6 is selected from H, CN, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, SF5, OR a or 5-6 membered heteroaryl; said 5-6 membered heteroaryl is optionally substituted by 1, 2 or 3 R z replace;
[0138] R z Selected from C 1-6 Alkyl, halogen, CN, C 1-6 Haloalkyl or C 1-6 alkoxy;
[0139] R a Selected from H, C 1-6 Alkyl or C 1-6 Halogenated alkyl.
[0140] In another more specific embodiment, the present invention provides a compound of formula (III-3), or a pharmaceutically acceptable salt, isotopic variant, tautomer or stereoisomer thereof:
[0141] R1 is selected from methyl, CD3, ethyl or cyclopropyl;
[0142] R6 is selected from H, CN, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, SF5, OR aor 5-6 membered heteroaryl; said 5-6 membered heteroaryl is optionally substituted by 1, 2 or 3 R z replace;
[0143] R z Selected from C 1-6 Alkyl, halogen, CN, C 1-6 Haloalkyl or C 1-6 alkoxy;
[0144] R a Selected from H, C 1-6 Alkyl or C 1-6 Halogenated alkyl.
[0145] In another embodiment, the present invention provides a compound of formula (IV-1), or a pharmaceutically acceptable salt, isotopic variant, tautomer or stereoisomer thereof:
[0146] R1 is selected from C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 3-6 Cycloalkyl or C 1-6 alkyl halide;
[0147] R x1 is selected from phenyl or 5-10 membered heteroaryl, wherein the phenyl or 5-10 membered heteroaryl is optionally substituted by 1, 2 or 3 R y replace;
[0148] R y Selected from halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, SF5, CN, OR a 、C 1-6 Alkoxy, C 3-6 Cycloalkyl, 4-12 membered heterocyclyl or 5-10 membered heteroaryl, wherein said 4-12 membered heterocyclyl or 5-10 membered heteroaryl is optionally substituted by 1, 2 or 3 R z replace;
[0149] R z Selected from C 1-6 Alkyl, halogen, CN, C 1-6 Haloalkyl or C 1-6 alkoxy;
[0150] R a Selected from H, C 1-6 Alkyl or C 1-6 Halogenated alkyl.
[0151] In another more specific embodiment, the present invention provides a compound of formula (IV-2), or a pharmaceutically acceptable salt, isotopic variant, tautomer or stereoisomer thereof:
[0152] in,
[0153] R1 is selected from methyl, CD3, ethyl or cyclopropyl;
[0154] R y Selected from C 1-6 Alkyl, C 1-6 Haloalkyl, CN, OR a 、C 1-6 Alkoxy, C 3-6 Cycloalkyl, 4-12 membered heterocyclyl or 5-10 membered heteroaryl, wherein said 4-12 membered heterocyclyl or 5-10 membered heteroaryl is optionally substituted by 1, 2 or 3 R z replace;
[0155] R z Selected from C 1-6 Alkyl, halogen, CN, C 1-6 Haloalkyl or C 1-6 alkoxy;
[0156] In another embodiment, the present invention provides a compound of formula (V-1), or a pharmaceutically acceptable salt, isotopic variant, tautomer or stereoisomer thereof:
[0157] in,
[0158] R1 is selected from C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 3-6 Cycloalkyl or C 1-6 alkyl halide;
[0159] R x1 is a 5-10 membered heteroaryl group, which is optionally substituted by 1, 2 or 3 R y replace;
[0160] R y Selected from halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, SF5, CN, OR a 、C 1-6 Alkoxy, C 3-6 Cycloalkyl, 4-12 membered heterocyclyl or 5-10 membered heteroaryl, wherein the 5-10 membered heteroaryl is optionally substituted by 1, 2 or 3 R z replace;
[0161] Rz Selected from C 1-6 Alkyl, halogen, CN, C 1-6 Haloalkyl or C 1-6 alkoxy;
[0162] R a Selected from H, C 1-6 Alkyl or C 1-6 Halogenated alkyl.
[0163] In another more specific embodiment, the present invention provides a compound of formula (V-2), or a pharmaceutically acceptable salt, isotopic variant, tautomer or stereoisomer thereof:
[0164] in,
[0165] R1 is selected from methyl, CD3, ethyl or cyclopropyl;
[0166] R y Selected from halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, SF5, CN, OR a 、C 1-6 Alkoxy, C 3-6 Cycloalkyl, 4-12 membered heterocyclyl or 5-10 membered heteroaryl, wherein the 5-10 membered heteroaryl is optionally substituted by 1, 2 or 3 R z replace;
[0167] R z Selected from C 1-6 Alkyl, halogen, CN, C 1-6 Haloalkyl or C 1-6 alkoxy;
[0168] R a Selected from H, C 1-6 Alkyl or C 1-6 Halogenated alkyl.
[0169] In another more specific embodiment, the present invention provides a compound of formula (V-3), or a pharmaceutically acceptable salt, isotopic variant, tautomer or stereoisomer thereof:
[0170] in,
[0171] R1 is selected from methyl, CD3, ethyl or cyclopropyl;
[0172] R z Selected from C 1-6 Alkyl, halogen, CN, C 1-6 Haloalkyl or C 1-6 alkoxy;
[0173] R a Selected from H, C 1-6 Alkyl or C 1-6 Halogenated alkyl.
[0174] In another embodiment, the present invention provides a compound of formula (VI-1) or (VII-1), or a pharmaceutically acceptable salt, isotopic variant, tautomer or stereoisomer thereof:
[0175] R1 is selected from H, C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 3-6 Cycloalkyl or C 1-6 alkyl halide;
[0176] R3 is selected from H, C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 3-6 Cycloalkyl or 4-10 membered heterocyclic group; said C 1-6 Alkyl or 4-10 membered heterocyclyl is optionally substituted with 1 or 2 R5;
[0177] R5 is selected from hydrogen, halogen, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl, C 1-6 Halogenated alkoxy, CN, SF5, C 3-6 Cycloalkyl, -S(O)2CF3, -OCF3, -SCF3, -SCH3 or 5-10 membered heteroaryl; said 5-10 membered heteroaryl is optionally further substituted by R6, R6 is selected from H, CN, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, SF5, OR a or a 5-6 membered heteroaryl group;
[0178] R a Selected from H, C 1-6 Alkyl or C 1-6 alkyl halide;
[0179] Z is selected from N or CH.
[0180] In some embodiments, R3 is selected from C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 3-6 Cycloalkyl or 4-10 membered heterocyclic group; said C 1-6 The alkyl or 4-10 membered heterocyclyl is optionally substituted with 1 or 2 R5.
[0181] In another more specific embodiment, the present invention provides a compound of formula (VI-2) or (VII-2), or a pharmaceutically acceptable salt, isotopic variant, tautomer or stereoisomer thereof:
[0182] R1 is selected from H, methyl, CD3, ethyl or cyclopropyl;
[0183] R3 is selected from H, C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 3-6 Cycloalkyl or 4-10 membered heterocyclic group;
[0184] R5 is selected from hydrogen, halogen, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl, C 1-6 Halogenated alkoxy, CN, SF5, C 3-6 Cycloalkyl, -S(O)2CF3, -OCF3, -SCF3, -SCH3 or 5-10 membered heteroaryl;
[0185] In some embodiments, R3 is selected from C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 3-6 Cycloalkyl or 4-10 membered heterocyclic group.
[0186] In another more specific embodiment, the compound of formula (VI-2) or (VII-2), or a pharmaceutically acceptable salt, isotopic variant, tautomer or stereoisomer thereof:
[0187] R1 is selected from H, methyl, CD3, ethyl or cyclopropyl;
[0188] R3 is selected from H, methyl, CD3, ethyl or cyclopropyl;
[0189] R5 is selected from hydrogen, F, Cl, Br, methyl, CD3, ethyl, methoxy, trifluoromethyl, difluoromethyl, CN, SF5, cyclopropyl, -S(O)2CF3, -OCF3, -OCF2Cl, -SCF3, -SCH3 or pyridyl.
[0190] In some embodiments, R3 is selected from methyl, CD3, ethyl, or cyclopropyl.
[0191] In some embodiments, the compound is
[0192] In some embodiments, the compound is
[0193] In some embodiments, the compound is
[0194] In some embodiments, the compound is
[0195] In some embodiments, the compound is
[0196] In some embodiments, the compound is
[0197] In some embodiments, R1 is selected from methyl or CD3.
[0198] In some embodiments, R3 is selected from H, C 1-6 Alkyl, deuterated C 1-6 Alkyl or C 3-6 In some embodiments, R3 is selected from C 1-6 Alkyl, deuterated C 1-6 Alkyl or C 3-6 In some embodiments, R3 is selected from H, methyl, CD3, ethyl, or cyclopropyl. In some embodiments, R3 is selected from methyl, CD3, ethyl, or cyclopropyl.
[0199] In some embodiments, R5 is selected from hydrogen, halogen, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl, C 1-6 Halogenated alkoxy, CN, SF5, C 3-6 Cycloalkyl, -S(O)2CF3, -OCF3, -SCF3, -SCH3 or pyridyl (e.g., pyridin-2-yl, pyridin-3-yl or pyridin-4-yl); the pyridyl is optionally further substituted by R6, R6 is selected from H, CN, halogen, C 1-6 Alkyl, C 1-6 In some embodiments, R is selected from hydrogen, F, Cl, Br, methyl, CD, ethyl, methoxy, trifluoromethyl, difluoromethyl, CN, SF, cyclopropyl-S(O)CF, -OCF, -SCF, -SCH, or pyridinyl (e.g., pyridin-2-yl, pyridin-3-yl, or pyridin-4-yl), optionally substituted with halogen.
[0200] In some embodiments, Z is selected from CH2 or NH.
[0201] In a more specific embodiment, the present invention provides a compound, or a tautomer, stereoisomer or pharmaceutically acceptable salt thereof, wherein the compound is selected from:
[0202] The compounds of the present invention may include one or more asymmetric centers and may therefore exist in a variety of stereoisomeric forms, for example, enantiomers and / or diastereomeric forms. For example, the compounds of the present invention may be individual enantiomers, diastereomers, or geometric isomers (e.g., cis and trans isomers), or may be in the form of mixtures of stereoisomers, including racemic mixtures and mixtures enriched in one or more stereoisomers. Isomers may be separated from the mixture by methods known to those skilled in the art, including chiral high pressure liquid chromatography (HPLC) and the formation and crystallization of chiral salts; or preferred isomers may be prepared by asymmetric synthesis.
[0203] The compounds of the present invention may also exist as tautomers. For compounds that exist in different tautomeric forms, a compound is not limited to any specific tautomer, but is intended to encompass all tautomeric forms.
[0204] The compounds of the present invention can be in amorphous or crystalline form (polymorph). In addition, the compounds of the present invention can exist in one or more crystalline forms. Therefore, the present invention includes all amorphous or crystalline forms of the compounds of the present invention within its scope. The term "polymorph" refers to the crystalline form (or its salt, hydrate or solvate) of a compound with a specific crystal packing arrangement. All polymorphs have the same elemental composition. Different crystalline forms typically have different X-ray diffraction patterns, infrared spectra, melting points, density, hardness, crystal shape, photoelectric properties, stability and solubility. Recrystallization solvent, crystallization rate, storage temperature and other factors can cause one crystalline form to dominate. The various polymorphs of a compound can be prepared by crystallization under different conditions.
[0205] The present invention also includes isotopically labeled compounds (isotopic variants) which are identical to those described in formula (A) except that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be introduced into the compounds of the present invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine and chlorine, for example 2 H. 3 H. 13 C. 11 C. 14 C. 15 N. 18 O. 17 O. 31 P. 32 P. 35 S. 18 F and 36Cl. Compounds of the present invention containing the above-mentioned isotopes and / or other isotopes of other atoms, their prodrugs and pharmaceutically acceptable salts of the compounds or prodrugs are within the scope of the present invention. Certain isotopically labeled compounds of the present invention, such as those in which radioactive isotopes (e.g. 3 H and 14 C) can be used in drug and / or substrate tissue distribution assays. 3 H and carbon-14, i.e. 14 C isotopes are particularly preferred because they are easy to prepare and detect. 2 H, because greater metabolic stability can provide therapeutic benefits, such as prolonged in vivo half-life or reduced dosage requirements, and thus may be preferred in some cases. Isotopically labeled compounds of formula (A) of the present invention and prodrugs thereof can generally be prepared by substituting readily available isotopically labeled reagents for non-isotopically labeled reagents when carrying out the processes disclosed in the following schemes and / or the Examples and Preparations.
[0206] Pharmaceutical compositions and kits
[0207] In another aspect, the present invention provides pharmaceutical compositions comprising a compound of the present invention (also referred to as an "active ingredient") and a pharmaceutically acceptable excipient. In some embodiments, the pharmaceutical composition comprises an effective amount of a compound of the present invention. In some embodiments, the pharmaceutical composition comprises a therapeutically effective amount of a compound of the present invention. In some embodiments, the pharmaceutical composition comprises a prophylactically effective amount of a compound of the present invention.
[0208] Pharmaceutically acceptable excipients used in the present invention refer to non-toxic carriers, adjuvants or vehicles that do not destroy the pharmacological activity of the compound formulated together. Pharmaceutically acceptable carriers, adjuvants or vehicles that can be used in the compositions of the present invention include (but are not limited to) ion exchangers, alumina, aluminum stearate, lecithin, serum proteins (such as human serum albumin), buffer substances (such as phosphates), glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes (such as protamine sulfate), disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, silica gel, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethyl cellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and lanolin.
[0209] The present invention also includes kits (e.g., pharmaceutical packaging). The kits provided may include a compound of the invention, other therapeutic agents, and first and second containers (e.g., vials, ampoules, bottles, syringes, and / or dispersible packaging or other suitable containers) containing the compound of the invention and other therapeutic agents. In some embodiments, the kit provided may also optionally include a third container containing a pharmaceutical excipient for diluting or suspending the compound of the invention and / or other therapeutic agents. In some embodiments, the compound of the invention and other therapeutic agents provided in the first and second containers are combined to form a unit dosage form.
[0210] Drug administration
[0211] Pharmaceutical compositions provided by the invention can be administered by many routes, including but not limited to: oral administration, parenteral administration, inhalation administration, topical administration, rectal administration, nasal administration, oral administration, vaginal administration, administration by implant or other modes of administration. For example, parenteral administration used herein includes subcutaneous administration, intradermal administration, intravenous administration, intramuscular administration, intraarticular administration, intraarterial administration, intrasynovial administration, intrasternal administration, intrathecal administration, intralesional administration, and intracranial injection or infusion technology.
[0212] Typically, an effective amount of the compounds provided herein is administered. The amount of compound actually administered can be determined by a physician based on the relevant circumstances, including the condition being treated, the route of administration selected, the compound actually administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the like.
[0213] When used to prevent the conditions described herein, the compounds provided herein are administered to a subject at risk of developing the condition, typically based on the advice and under the supervision of a physician, at dosage levels as described above. Subjects at risk of developing a particular condition typically include those with a family history of the condition, or those identified by genetic testing or screening as being particularly susceptible to developing the condition.
[0214] The pharmaceutical compositions provided herein can also be administered long-term ("chronic administration"). Long-term administration refers to administration of a compound or pharmaceutical composition thereof over an extended period of time, e.g., 3 months, 6 months, 1 year, 2 years, 3 years, 5 years, etc., or administration can continue indefinitely, e.g., for the remainder of the subject's life. In some embodiments, long-term administration is intended to provide a constant level of the compound in the blood over an extended period of time, e.g., within the therapeutic window.
[0215] Various methods of administration can be used to further deliver the pharmaceutical composition of the present invention. For example, in some embodiments, the pharmaceutical composition can be administered by injection, for example, in order to increase the concentration of the compound in the blood to an effective level. The bolus dose depends on the target systemic level of the active ingredient by the body, for example, an intramuscular or subcutaneous bolus dose slowly releases the active ingredient, and the bolus (for example, by IV intravenous drip) delivered directly to the vein can be delivered more quickly so that the concentration of the active ingredient in the blood is rapidly increased to an effective level. In other embodiments, the pharmaceutical composition can be given in a continuous infusion form, for example, by IV intravenous drip, so as to provide a steady-state concentration of the active ingredient in the subject's body. In addition, in other embodiments, the pharmaceutical composition of the bolus dose can be first given, and then continuous infusion.
[0216] Oral compositions can be in the form of bulk liquid solutions or suspensions or bulk powders. However, more generally, in order to facilitate accurate dosing, the compositions are provided in unit dosage form. The term "unit dosage form" refers to a physically discrete unit suitable as a unit dose for human patients and other mammals, each unit containing a predetermined amount of active substance suitable for producing the desired therapeutic effect and a suitable pharmaceutical excipient. Typical unit dosage forms include pre-filled, pre-measured ampoules or syringes of liquid compositions, or pills, tablets, capsules, etc. in the case of solid compositions. In such compositions, the compound is typically a minor component (about 0.1 to about 50% by weight, or preferably about 1 to about 40% by weight), with the remainder being various carriers or excipients and processing aids useful for forming the desired dosage form.
[0217] For oral dosage, a representative regimen is one to five oral doses per day, particularly two to four oral doses, typically three oral doses. Using these dosage administration modes, each dose provides about 0.01 to about 20 mg / kg of the compound of the invention, with preferred doses each providing about 0.1 to about 10 mg / kg, particularly about 1 to about 5 mg / kg.
[0218] To provide blood levels similar to, or lower than, those obtained with an injectable dose, a transdermal dose is typically selected in an amount of about 0.01 to about 20% by weight, preferably about 0.1 to about 20% by weight, preferably about 0.1 to about 10% by weight, and more preferably about 0.5 to about 15% by weight.
[0219] From about 1 to about 120 hours, and particularly from 24 to 96 hours, the injected dose level is in the range of about 0.1 mg / kg / hour to at least 10 mg / kg / hour. To achieve adequate steady-state levels, a preload bolus of about 0.1 mg / kg to about 10 mg / kg or more may also be administered. For a 40 to 80 kg human patient, the maximum total dose may not exceed about 2 g / day.
[0220] Liquid forms suitable for oral administration may include a suitable aqueous or non-aqueous carrier and buffers, suspending and dispersing agents, colorants, flavorings, etc. Solid forms may include, for example, any of the following components, or compounds of a similar nature: binders such as microcrystalline cellulose, tragacanth, or gelatin; excipients such as starch or lactose; disintegrants such as alginic acid, Primogel, or corn starch; lubricants such as magnesium stearate; glidants such as colloidal silicon dioxide; sweeteners such as sucrose or saccharin; or flavorings such as peppermint, methyl salicylate, or orange flavor.
[0221] Injectable compositions are typically based on sterile saline or phosphate buffered saline for injection, or other injectable excipients known in the art. As previously mentioned, in such compositions, the active compound is typically a minor component, often about 0.05 to 10% by weight, with the remainder being injectable excipients and the like.
[0222] Typically, transdermal compositions are formulated as topical ointments or creams containing the active ingredient. When formulated as an ointment, the active ingredient is typically combined with a paraffin or water-miscible ointment base. Alternatively, the active ingredient can be formulated into a cream together with, for example, an oil-in-water cream base. Such transdermal formulations are well known in the art and typically include other components that enhance the stable skin penetration of the active ingredient or formulation. All such known transdermal formulations and components are included within the scope provided by the present invention.
[0223] The compounds of the present invention may also be administered by transdermal devices.Thus, transdermal administration may be achieved using patches of the reservoir or porous membrane type, or various solid matrices.
[0224] The above components for oral administration, injection or topical administration are representative only. Other materials and processing techniques are described in Part 8 of Remington's Pharmaceutical Sciences, 17th edition, 1985, Mack Publishing Company, Easton, Pennsylvania, which is incorporated herein by reference.
[0225] The compounds of the invention can also be administered in sustained release form or from a sustained release delivery system. Descriptions of representative sustained release materials can be found in Remington's Pharmaceutical Sciences.
[0226] The present invention also relates to pharmaceutically acceptable formulations of the compounds of the present invention. In one embodiment, the formulation comprises water. In another embodiment, the formulation comprises a cyclodextrin derivative. The most common cyclodextrins are α-, β-, and γ-cyclodextrins consisting of 6, 7, and 8 α-1,4-linked glucose units, respectively, which optionally include one or more substituents on the linked sugar portion, including but not limited to: methylated, hydroxyalkylated, acylated, and sulfoalkyl ether substitutions. In some embodiments, the cyclodextrin is a sulfoalkyl ether β-cyclodextrin, for example, sulfobutyl ether β-cyclodextrin, also known as Captisol. See, for example, US5,376,645. In some embodiments, the formulation includes hexapropyl-β-cyclodextrin (e.g., in water, 10-50%).
[0227] Example
[0228] The reagents used in the present invention are commercial reagents purchased directly or synthesized using common methods well known in the art.
[0229] Notes on commonly used abbreviations:
[0230] Abbreviations: PE = petroleum ether; EA = ethyl acetate; MeOH = methanol; DCM = dichloromethane; DCE = dichloroethane; CH3CN = acetonitrile; 1,4-dioxane = 1,4-dioxane; DMSO = dimethyl sulfoxide; HFIP = hexafluoroisopropanol; DMF = N,N-dimethylformamide; Hex = n-hexane; IPA = isopropanol; NMP = N-methylpyrrolidone; NMO = N-methylmorpholine-N-oxygenase compound; TEA = triethylamine; DIEA = diisopropylethylamine; CuI = cuprous iodide; CuCN = cuprous cyanide; triphosgene = triphosgene; p-TsOH = p-toluenesulfonic acid; T3P = 1-propylphosphonic acid cyclic anhydride; TsN3 = p-toluenesulfonyl azide; PPA = polyphosphoric acid; BINAP = 1,1'-binaphthyl-2,2'-bis(diphenylphosphine); m-CPBA = m-chloroperoxybenzoic acid; Hex = n-hexane.
[0231] MTAPwt = methylthioadenosine phosphorylase wild type;
[0232] MTAPdel = methylthioadenosine phosphorylase deficiency;
[0233] MTA = methylthioadenosine;
[0234] SAM = adenosylmethionine.
[0235] The specific reaction routes or steps exemplified below are used in the present invention, and are as follows:
[0236] Example 1
[0237] Preparation of key intermediates a1-a43
[0238] Synthesis of intermediates a1, a7-a8, and a27
[0239] Step 1: Dissolve the raw material 4-bromo-1-pyrazolo[3,4-c]pyridine a1-1 (1.1 g, 5.2 mmol) in 20 mL of dichloromethane. Slowly add the oxidizing agent m-chloroperbenzoic acid (m-CPBA) (1.3 g, 7.8 mmol). Allow to react at room temperature for 3 hours, then stop the reaction. Filter, wash the filter cake with dichloromethane, and dry to obtain a1-2 (1.0 g) as a white solid in an 84% yield.
[0240] Step 2: Dissolve the intermediate a1-2 (1.0 g, 4.4 mmol) from the previous step in 10 mL of acetonitrile in an ice bath. Slowly add POCl3 (1.0 mL) dropwise. Incubate the mixture in an ice bath for 1 hour to stop the reaction. Evaporate the solvent under reduced pressure, add 50 mL of ice water, and adjust the pH to approximately 8 with saturated sodium bicarbonate solution. Extract with dichloromethane, dry over anhydrous sodium sulfate, and concentrate. The crude product is separated by flash reverse-phase column chromatography (C18, CH3CN / H2O, 4 / 5) to afford a1-3 (900 mg) as a white solid in an 83% yield. LCMS ESI-MS m / z: 246 [M+H] + .
[0241] Step 3: Under nitrogen, intermediate a1-3 (900 mg, 3.65 mmol), benzophenone imine (2.6 g, 14.6 mmol), and cesium carbonate (4.8 g, 14.6 mmol) were dissolved in 27 mL of anhydrous toluene. Catalyst Pd(OAc)2 (164 mg, 0.73 mmol) and ligand BINAP (900 mg, 1.46 mmol) were added. The mixture was heated to 140°C and reacted for 7 hours, after which the reaction was stopped. The mixture was filtered, and the solvent was evaporated under reduced pressure. The crude product was directly separated by flash reverse phase column chromatography (C18, CH3CN / H2O, 4 / 5) to afford a1-4 (400 mg) as a white solid in a 22% yield. LCMS ESI-MS m / z: 492 [M+H] + .
[0242] Step 4: Dissolve the intermediate a1-4 (400 mg, 0.81 mmol) from the previous step in 2 mL of tetrahydrofuran and add 8 mL of dilute hydrochloric acid (2 M) dropwise. React at room temperature for 3 hours to stop the reaction. Add saturated sodium bicarbonate solution to the reaction solution, adjust the pH to approximately 8, extract with ethyl acetate, dry over anhydrous sodium sulfate, and concentrate. The crude product is separated by flash reverse-phase column chromatography (C18, CH3CN / H2O, 1 / 3) to obtain the target intermediate a1 (100 mg) in a yield of 75%. LCMS ESI-MS m / z: 164 [M+H] + .
[0243] Referring to the synthetic route of compound a1, similar raw materials / intermediates were used to synthesize the following target intermediates.
[0244] Synthesis of intermediates a2-a5, a9-a26, a28-a32, a35-a37, a40-a42:
[0245] Step 1: Dissolve intermediate e1 (200 mg, 0.71 mmol) and triethylamine (143 mg, 1.42 mmol) in 4 mL of dichloromethane. Add methyl oxalyl chloride (134 mg, 1.1 mmol). React at room temperature for 1 hour. Evaporate the solvent under reduced pressure to obtain crude compound a2-1, which is directly used in the next step.
[0246] Step 2: Dissolve crude compound a2-1 (30 mg, 0.05 mmol) in 6 mL of a mixture of tetrahydrofuran and water (v / v, 1 / 1). Add LiOH (65 mg, 1.62 mmol) and react at room temperature for 4 hours. Slowly add dilute hydrochloric acid (4 M) dropwise to adjust the pH to approximately 6. Evaporate the solvent under reduced pressure, and separate the crude product by reverse-phase chromatography on a flash column (C18, CH3CN / H2O, 1 / 1) to afford compound a2 (110 mg). The total yield for the two steps is 43%. LCMS ESI-MS m / z: 355 [M+H] + .
[0247] Referring to the synthetic route of compound a2 or intermediate a2-1, similar raw materials / intermediates were used to synthesize the following target intermediate.
[0248] Synthesis of intermediate a6:
[0249] Step 1: In an ice bath, under nitrogen, dissolve the starting material a6-1 (800 mg, 3.75 mmol) and methanol (183 mg, 5.63 mmol) in 16 mL of anhydrous tetrahydrofuran. Add diisopropyl azodicarboxylate (DIAD) (134 mg, 1.1 mmol) and PPh3 (1.18 g, 4.50 mmol). React at room temperature for 1 hour. The precipitated solid is filtered. The filtrate is concentrated under reduced pressure to afford a6-2 (290 mg) as a white solid in a 34% yield. LCMS ESI-MS m / z: 227 [M+H] + .
[0250] Step 2: Under nitrogen, the intermediate a6-2 (290 mg, 1.27 mmol), benzophenone imine (347 mg, 1.91 mmol), and cesium carbonate (1.7 g, 5.2 mmol) were dissolved in 9 mL of anhydrous toluene. Catalyst Pd(OAc)2 (29 mg, 0.12 mmol) and ligand BINAP (159 mg, 0.25 mmol) were added. The mixture was heated to 140°C and reacted for 48 hours, after which the reaction was stopped. The mixture was filtered and the solvent was evaporated under reduced pressure to obtain crude product a6-3. LCMS ESI-MS m / z: 328 [M+H] + .
[0251] Step 3: Dissolve the crude product a6-3 (230 mg, 0.70 mmol) from the previous step in 5 mL of tetrahydrofuran and add 3 mL of dilute hydrochloric acid (2 M) dropwise. React at room temperature for 2 hours to stop the reaction. Saturated sodium bicarbonate solution is added to the reaction solution to adjust the pH to approximately 8. Extract with ethyl acetate, dry over anhydrous sodium sulfate, and concentrate. The crude product is separated by flash reverse-phase column chromatography (C18, CH3CN / H2O, 3 / 5) to obtain the target intermediate a6 (70 mg) in a 61% yield. LCMS ESI-MS m / z: 164 [M+H] + .
[0252] Synthesis of intermediates a33-a34, a38, and a43:
[0253] Step 1: Under nitrogen, intermediate a31 (120 mg, 0.36 mmol), ligand BrettPhos (39.2 mg, 0.07 mmol), and catalyst Pd(COD)(CH2TMS)2 (28.4 mg, 0.07 mmol) were dissolved in 3 mL of anhydrous toluene. The mixture was heated to 80°C and stirred for 10 minutes. AgSCF3 (99 mg, 0.47 mmol) and triethylphenylammonium iodide PhEt3NI (145 mg, 0.47 mmol) were added to the reaction mixture, and the mixture was allowed to react at 80°C for 2 hours before quenching the reaction. The mixture was filtered, and the solvent was evaporated under reduced pressure. The crude product was separated by flash reverse phase column chromatography (C18, CH3CN / H2O, 9 / 10) to afford a33 (100 mg) as a brown oil in a 78% yield. LCMS ESI-MS m / z: 350 [M+H] + .
[0254] Step 2: Dissolve the intermediate a33 (100 mg, 0.28 mmol) from the previous step in 2 mL of a mixture of tetrahydrofuran and water (v / v, 1 / 1). Add a 0.5 mL 1N aqueous LiOH solution dropwise and allow to react at room temperature for 1 hour to terminate the reaction. Dilute hydrochloric acid was added to the reaction solution to adjust the pH to approximately 5. The solvent was evaporated under reduced pressure, and the crude product was separated by flash reverse-phase column chromatography (C18, CH3CN / H2O, 1 / 1) to obtain the target intermediate a34 (50 mg) in a 54% yield. LCMS ESI-MS m / z: 322 [M+H] + .
[0255] Referring to the synthetic route of compound a34, similar raw materials / intermediates were used to synthesize the following target intermediate.
[0256] Synthesis of intermediate a39:
[0257] Step 1: Dissolve intermediate a33 (360 mg, 1.03 mmol) in 8 mL of chloroform in an ice bath. Stir for 5 minutes, then add m-CPBA (531 mg, 3.09 mmol). Warm the mixture to 60°C and allow to react for 12 hours, then stop the reaction. Filter, add 10 mL of saturated sodium thiosulfate solution, extract with dichloromethane, dry over anhydrous sodium sulfate, and evaporate the solvent under reduced pressure to obtain a39-1 (480 mg) as a brown oil in a 90% yield. LCMS ESI-MS m / z: 382 [M+H] + .
[0258] Step 2: Dissolve the intermediate a39-1 (480 mg, 0.92 mmol) in 7 mL of tetrahydrofuran in an ice bath. After stirring for 5 minutes, add a 2N aqueous solution of LiOH (1.0 mL). The mixture is allowed to react at room temperature for 1 hour, after which the reaction is stopped. The solvent is evaporated under reduced pressure, and dilute hydrochloric acid is added to the reaction mixture to adjust the pH to approximately 5. The mixture is extracted with ethyl acetate, dried over anhydrous sodium sulfate, and concentrated. The crude product is separated by flash reverse column chromatography (C18, CH3CN / H2O, 1 / 1) to afford a39 (190 mg) as a white solid in a 58% yield. LCMS ESI-MS m / z: 354 [M+H] + .
[0259] Preparation of key intermediates b1-b5
[0260] Synthesis of intermediates b1-b2, b4-b9
[0261] Step 1: Under nitrogen at -78°C, dissolve raw material b1-1 (8.8 g, 41.3 mmol) in 88 mL of anhydrous tetrahydrofuran. Slowly add a solution of LiHMDS in tetrahydrofuran (10.4 g, 61.9 mmol, 61.9 mL) dropwise. Stir at -78°C for 1.5 hours. Add N-phenylbis(trifluoromethanesulfonyl)imide (20.1 g, 51.6 mmol) to the reaction mixture, warm to room temperature, and allow to react for 2 hours before stopping the reaction. Add 50 mL of ice water to the reaction mixture, extract with methyl tert-butyl ether, dry over anhydrous sodium sulfate, and concentrate. The crude product is separated by flash reverse-phase column chromatography (C18, CH3CN) to obtain b1-2 (10.1 g) as a red oil in a 71% yield. LCMS ESI-MS m / z: 346 [M+H] + .
[0262] Step 2: Under nitrogen, the oil from the previous step b1-2 (2.1 g, 6.08 mmol), 5-boronic acid pinacol ester-1,3-benzothiazole b1-3 (1.1 g, 7.62 mmol), and sodium carbonate (1.9 g, 18.2 mmol) were dissolved in 40 mL of a mixture of 1,4-dioxane and water (v / v, 3 / 1). Catalyst Pd(dppf)Cl2 (220 mg, 0.30 mmol) was added. The mixture was heated to 80°C and reacted for 2 hours, after which the reaction was stopped. The mixture was filtered, and 100 mL of water was added. The mixture was extracted with ethyl acetate, dried over anhydrous sodium sulfate, and concentrated to afford b1-3 (2.7 g) as a white solid in a 96% yield. LCMS ESI-MS m / z: 331 [M+H] + .
[0263] Step 3: Dissolve the white solid b1-3 (2.7 g, 8.17 mmol) from the previous step in 15 mL of trifluoroacetic acid and allow to react at room temperature for 1 hour. The reaction was then stopped. The solvent was evaporated under reduced pressure, and the reaction mixture was adjusted to pH 8 by adding saturated aqueous sodium bicarbonate. The mixture was extracted with ethyl acetate, dried over anhydrous sodium sulfate, and concentrated to afford b1-4 (1.8 g) as a yellow oil in a 96% yield. LCMS ESI-MS m / z: 231 [M+H] + .
[0264] Step 4: Dissolve the oil b1-4 (1.0 g, 4.34 mmol) in 20 mL of methanol in an ice bath. Add the reducing agent NaBH4 (250 mg, 6.51 mmol). React for 1 hour in an ice bath, then stop the reaction. Add 100 mL of ice water to the reaction solution, extract with ethyl acetate, dry over anhydrous sodium sulfate, and concentrate. The crude product is separated by flash reverse-phase column chromatography (C18, CH3CN / H2O, 3 / 5) to obtain a yellow oil b1 (370 mg) in a 37% yield. LCMS ESI-MS m / z: 233 [M+H] + .
[0265] Referring to the synthetic route of compound b1, similar raw materials / intermediates were used to synthesize the following target intermediate.
[0266] Synthesis of intermediates b3, b10-b13
[0267] Step 1: Under nitrogen, dissolve the raw material 2-methyl-5-bromo-1,3-benzothiazole b3-1 (1.2 g, 5.26 mmol) in 6 mL of ethylene glycol. Slowly add a 40% aqueous solution of NaOH (6 mL) dropwise. Heat to 140°C and react for 4 hours before cooling to room temperature. Add 50 mL of ice water to the reaction mixture, adjust the pH to approximately 6 with dilute hydrochloric acid, extract with dichloromethane, dry over anhydrous sodium sulfate, and concentrate to obtain b3-2 (900 mg), a yellow solid, in a 42% yield. LCMS ESI-MS m / z: 405 [M+H] + .
[0268] Step 2: Dissolve 1-methyl-4-piperidinic acid b3-3 (630 mg, 4.44 mmol) in 14 mL of PPA, heat to 160°C, and stir for 30 minutes. Add intermediate b3-2 (900 mg, 2.22 mmol) from the previous step. Heat the mixture to 180°C and react for 3 hours, then stop the reaction. Pour the mixture into 100 mL of ice water and adjust the pH to approximately 8 with saturated sodium bicarbonate solution. Extract with ethyl acetate, dry over anhydrous sodium sulfate, and concentrate. The crude product is separated by flash column chromatography (C18, CH3CN / H2O, 3 / 5) to obtain b3-4 (250 mg) as a yellow solid in a 36% yield. LCMS ESI-MS m / z: 311 [M+H] + .
[0269] Step 3: Under nitrogen, the yellow solid b3-4 (3.0 g, 9.64 mmol), pinacol diboron (2.9 g, 11.6 mmol), and KOAc (2.8 g, 28.9 mmol) were dissolved in 30 mL of 1,4-dioxane. Catalyst Pd(dppf)Cl2 (390 mg, 0.48 mmol) was added. The mixture was heated to 90°C and reacted for 2 hours, after which the reaction was stopped. The mixture was filtered, and 100 mL of water was added. The mixture was extracted with ethyl acetate, dried over anhydrous sodium sulfate, and concentrated to afford a brown solid b3 (2.7 g) in a 78% yield. LCMS ESI-MS m / z: 359 [M+H] + .
[0270] Referring to the synthetic route of compound b3, similar raw materials / intermediates were used to synthesize the following target intermediate.
[0271] Preparation of key intermediates C1-C4
[0272] Synthesis of intermediates C1-C4
[0273] Step 1: Under nitrogen, dissolve the starting materials 5-trifluoromethyl-pyridine-2-carbaldehyde c1-1 (558 mg, 3.53 mmol) and c1-2 (508 mg, 1.34 mmol) in 5.0 mL of dichloromethane. Add 4A molecular sieves (1.0 g) and allow to react at room temperature for 12 hours. The reaction is then stopped. Filter and concentrate the filtrate under reduced pressure to obtain c1-3 (600 mg) as a yellow oil. Yield: 84%. LCMS ESI-MS m / z: 537 [M+H]. + .
[0274] Step 2: Under nitrogen, 2,6-lutidine (48 mg, 0.45 mmol) and the catalyst Cu(OTf)2 (162 mg, 0.45 mmol) were dissolved in 3 mL of hexafluoroisopropanol and reacted at room temperature for 7 hours. Intermediate c1-3 (600 mg, 1.12 mmol) was added dropwise to the reaction solution. After addition, the reaction was continued for 10 hours before stopping. 6 mL of aqueous ammonia was added to the reaction solution, and after stirring for 1 hour, the solution was extracted with dichloromethane, dried over anhydrous sodium sulfate, and concentrated. The crude product was separated by flash column chromatography (PE / EA, 1 / 1) to obtain intermediate c1 (140 mg) with cis configuration in a yield of 51%. LCMS ESI-MS m / z: 247 [M+H] + .
[0275] Referring to the synthetic route of compound c1, the following target molecule was synthesized using a similar skeleton structure.
[0276] Preparation of key intermediates d1-d17
[0277] Synthesis of intermediates d1-d3, d5-d8, d11, d15-d17
[0278] Step 1: Under nitrogen, dissolve the raw material 2-hydroxy-4-trifluoromethylbenzaldehyde d1-1 (1.0 g, 5.26 mmol) and a tetrahydrofuran solution of methylamine (5.3 mL, 2 M) in 20 mL of anhydrous dichloromethane. Add magnesium sulfate (2.5 g, 21.0 mmol) and allow to react at room temperature for 12 hours, then stop the reaction. Filter and concentrate the filtrate under reduced pressure to obtain d1-2 (470 mg) as a yellow solid in a 44% yield. LCMS ESI-MS m / z: 204 [M+H] + .
[0279] Step 2: Under nitrogen, trimethylsulfoxide iodide (1.27 g, 5.78 mmol) and potassium tert-butoxide (649 mg, 5.78 mmol) were dissolved in 13 mL of anhydrous tetrahydrofuran and stirred for 30 minutes. Intermediate d1-2 (470 mg, 2.31 mmol) was added to the reaction solution, heated to 50°C for 4 hours, and cooled to room temperature. Potassium tert-butoxide (260 mg, 2.31 mmol) was added to the reaction solution, and the reaction was continued at room temperature for 12 hours. The reaction was stopped and filtered. The solvent was evaporated under reduced pressure, and the crude product was separated by flash reverse column chromatography (C18, CH3CN / H2O, 1 / 1) to obtain white d1 (40 mg) in an 8% yield. LCMS ESI-MS m / z: 218 [M+H] + .
[0280] Referring to the synthetic route of intermediate d1, the following intermediate was synthesized.
[0281] Synthesis of intermediates d4, d9-d10:
[0282] Step 1: Under nitrogen, dissolve raw materials d4-1 (12.2 g, 81.0 mmol) and d4-2 (13.6 g, 81.0 mmol) in 20 mL of acetic acid. Add ammonium acetate (12.5 g, 162 mmol), heat to 120°C, react for 1 hour, and cool to room temperature. Add 100 mL of ice water to the reaction solution, extract three times with methyl tert-butyl ether, combine the organic phases, dry over anhydrous sodium sulfate, and concentrate. The crude product is separated by flash column chromatography (PE / EA, 20 / 1) to obtain d4-3 (10.5 g) as a white solid in a 51% yield. LCMS ESI-MS m / z: 254 [M+H] + .
[0283] Step 2: Under nitrogen, the intermediate d4-3 (10.5 g, 41.4 mmol) and methyl 2-hydroxyacetate (7.5 g, 82.8 mmol) from the previous step were dissolved in 105 mL of DMF. NaH (3.3 g, 82.8 mmol, 60%) was added and the mixture was allowed to react at room temperature for 2 hours. 300 mL of ice water was added to the reaction solution, and the mixture was extracted three times with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated to afford d4-4 (5.0 g) as a yellow oil in a 44% yield. LCMS ESI-MS m / z: 276 [M+H] + .
[0284] Step 3: Dissolve the intermediate d4-4 (5.0 g, 18.2 mmol) from the previous step in 50 mL of ethanol, add concentrated hydrochloric acid (100 mL, 12 M), heat to 100°C, react for 1 hour, and cool to room temperature. Add 300 mL of aqueous ammonia dropwise to the reaction solution, extract three times with ethyl acetate, combine the organic phases, dry over anhydrous sodium sulfate, and concentrate. The crude product is separated by flash column chromatography (PE / EA, 10 / 1) to obtain d4-5 (366 mg) as a yellow solid in a 9% yield. LCMS ESI-MS m / z: 218 [M+H] + .
[0285] Step 4: Under nitrogen, the intermediate d4-5 (110 mg, 0.51 mmol) and a tetrahydrofuran solution of methylamine (1.3 mL, 2 M) were dissolved in 1 mL of trifluoroethanol and stirred at room temperature for 16 hours. NaBH4 (96 mg, 2.5 mmol) and 0.25 mL of methanol were added to the reaction solution, and the reaction was continued at room temperature for 1 hour before stopping the reaction. The filtrate was filtered, concentrated under reduced pressure, and the crude product was separated by flash reverse column chromatography (C18, CH3CN / H2O, 7 / 10) to obtain d4 (60 mg) as a white solid in a 51% yield. LCMS ESI-MS m / z: 233 [M+H] + .
[0286] Referring to the synthetic route of intermediate d4, the following intermediate was synthesized.
[0287] Synthesis of intermediates d12-d14:
[0288] Step 1: Under nitrogen, intermediate d11 (1.0 g, 4.4 mmol), potassium carbonate (1.2 g, 8.77 mmol), and starting material 5-chloro-pyridine-3-boronic acid e6-2 (1.0 g, 4.4 mmol) were dissolved in 20 mL of a mixture of 1,4-dioxane and water (v / v, 4 / 1). Catalyst Pd(dppf)Cl2 (321 mg, 0.44 mmol) was added. The mixture was heated to 100°C for 1 hour, filtered, and the solvent was evaporated under reduced pressure. The mixture was added with 100 mL of water, extracted with ethyl acetate, dried over anhydrous sodium sulfate, and concentrated. The crude product was separated by flash reverse-phase column chromatography (C18, CH3CN / H2O, 6 / 10) to afford d12 (960 mg) as a yellow oil in an 84% yield. LC-MS: [M+H] + =261.
[0289] Referring to the synthetic route of intermediate d12, the following intermediate was synthesized.
[0290] Preparation of key intermediates e1-e9
[0291] Synthesis of intermediates e1-e4
[0292] Steps: Under nitrogen protection, raw material e1-1 (558 mg, 3.53 mmol) and raw material e1-2 (618 mg, 3.53 mmol) were dissolved in 13 mL of dichloromethane, and NaBH(OAc)3 (2.25 g, 10.6 mmol) was added. The reaction was allowed to react at room temperature for 1 hour, and the reaction was stopped. The solvent was evaporated under reduced pressure, and the mixture was dissolved in 2 mL of methanol. Ammonia water was added to the system to adjust the pH to about 8, and the solvent was evaporated under reduced pressure. The mixture was separated by flash reverse column chromatography (C18, CH3CN / H2O, 4 / 5) to obtain a green oil e1 (320 mg). Yield: 29%. LC-MS: [M+H] + =283.
[0293] Referring to the synthetic route of compound c1, the following target molecule was synthesized using a similar skeleton structure.
[0294] Synthesis of intermediate e5
[0295] Step 1: Under nitrogen, the starting material 1-methyl-1,2,4-triazole-3-carbaldehyde e5-1 (3.1 g, 27.9 mmol) and the starting material (R)-configured tert-butylsulfenamide (3.4 g, 27.9 mmol) were dissolved in 62 mL of anhydrous toluene. KHSO4 (3.8 g, 27.9 mmol) was added and the mixture was heated to 50°C for 12 hours. The mixture was cooled to room temperature and filtered. The solvent was evaporated from the filtrate under reduced pressure to obtain an oily product e5-2 (4.9 g) in a 91% yield. LCMS ESI-MS m / z: 215 [M+H] + .
[0296] Step 2: Under nitrogen at -78°C, the oily product e5-2 (4.9 g, 22.87 mmol) from the previous step was dissolved in 98 mL of anhydrous tetrahydrofuran. A hexane solution of the Grignard reagent methylmagnesium bromide (45.8 mL, 45.73 mmol) was added dropwise. The reaction was continued at this temperature for 45 minutes. The temperature was slowly raised to room temperature, and the reaction was quenched by the addition of 100 mL of saturated aqueous sodium bicarbonate. The organic solvent was evaporated under reduced pressure, and the product was extracted with dichloromethane, dried over anhydrous sodium sulfate, and concentrated. The crude product was separated by flash reverse phase column chromatography (C18, CH3CN / H2O, 7 / 10) to obtain the oily product e5-3 (1.1 g) in a yield of 21%. LCMS ESI-MS m / z: 231 [M+H] + .
[0297] Step 3: Under nitrogen, the intermediate e5-3 (2.1 g, 9.12 mmol) from the previous step was dissolved in 42 mL of methanol. A solution of hydrogen chloride in dioxane (3.7 mL, 14.6 mmol) was added and the mixture was allowed to react at room temperature for 1 hour. The reaction was then stopped. 30 mL of water was added to the system, and the mixture was extracted with methyl tert-butyl ether, dried over anhydrous sodium sulfate, and concentrated to afford compound e5 (1.8 g) in a 95% yield. LCMS ESI-MS m / z: 127 [M+H] + .
[0298] Synthesis of intermediates e6-e9
[0299] Step 1: Under nitrogen, the starting material 5-bromo-2-pyridine c6-1 (2.9 g, 15.7 mmol), potassium carbonate (4.4 g, 31.5 mmol), and the starting material 5-chloro-pyridine-3-boronic acid e6-2 (22.5 g, 15.7 mmol) were dissolved in 58 mL of a mixture of 1,4-dioxane and water (v / v, 2 / 1). Catalyst Pd(dppf)Cl2 (929 mg, 1.57 mmol) was added. The mixture was heated to 100°C for 1 hour, filtered, and the solvent was evaporated under reduced pressure. The mixture was added with 100 mL of water, extracted with ethyl acetate, dried over anhydrous sodium sulfate, and concentrated. The crude product was separated by flash column chromatography (PE / EA, 5 / 1) to afford e6-3 (2.5 g) as a yellow solid in a 73% yield. LC-MS: [M+H] + =219.
[0300] Step 2: Dissolve the intermediate e6-3 (1.0 g, 4.5 mmol), triethylamine (0.9 g, 9.15 mmol), and starting material e1-1 (700 mg, 5.03 mmol) in 20 mL of dichloromethane in an ice bath under nitrogen. Add the reducing agent NaBH3 (1.1 g, 5.48 mmol) and acetic acid (0.3 g, 5.03 mmol). React for 2 hours in an ice bath, then stop the reaction. Add ammonia to the mixture to adjust the pH to approximately 8. The solvent is evaporated under reduced pressure, and the crude product is separated by flash reverse-phase column chromatography (C18, CH3CN / H2O, 3 / 5) to obtain e6 (612 mg) as a yellow oil in a 41% yield. LC-MS: [M+H] + =326.
[0301] Referring to the synthetic route of compound e6, similar raw materials / intermediates were used to synthesize the following target molecular intermediates.
[0302] Chiral resolution of key intermediates f1-f24
[0303] Synthesis of intermediate f1-f2
[0304] Separation conditions: chromatographic column: CHIRALPAKAS3; mobile phase: Hex (0.1% TFA): EtOH = 90:10; flow rate: 1.0 mL / min;);
[0305] f1 (retention time: 2.767 min; 105 mg, yield: 35%); 1 H NMR (300MHz, DMSO-d6) δ7.50(dd,J=26.1,7.8Hz,1H),7.39–7.23(m,2H),5.92(ddd,J=163.8,8.8,4.0Hz,1H),4.82–4.57(m,2H),2.58(d,J=39.0Hz,3H).
[0306] f2 (retention time: 3.853 min; 110 mg, yield: 37%).
[0307] Synthesis of intermediates f3-f4
[0308] Separation conditions: Chromatographic column: CHIRALPAK IF, 2*25 cm, 5 μm; Mobile phase A: Hex (0.5% 2 M NH3-MeOH), Mobile phase B: MeOH:DCM = 1:1; Flow rate: 20 mL / min;
[0309] f3 (retention time: 1.203 min; 150 mg);
[0310] f4 (retention time: 1.593 min; 150 mg).
[0311] Synthesis of intermediates f5-f6
[0312] Separation conditions: Chromatographic column: CHIRAL ART Cellulose-SB 5*25cm, 5μm; Mobile phase A: Hex (0.5% 2M NH3-MeOH), Mobile phase B: MeOH:DCM = 1:1; Flow rate: 1mL / min;
[0313] f5 (retention time: 12.455 min; 110 mg);
[0314] f6 (retention time: 13.892 min; 110 mg).
[0315] Synthesis of intermediates f7-f8
[0316] Separation conditions: chromatographic column CHIRALPAK IF, 2*25 cm, 5 μm; mobile phase A: Hex (0.1% TFA), mobile phase B: EtOH, flow rate: 20.0 mL / min;
[0317] f7 (retention time: 12.417 min; 130 mg);
[0318] f8 (retention time: 17.931 min; 115 mg).
[0319] Synthesis of intermediates f9-f10
[0320] Separation conditions: Chromatographic column: CHIRALPAK AS-H, 2*25 cm, 5 μm; Mobile phase A: Hex (0.4% TFA), Mobile phase B: EtOH, Flow rate: 20.0 mL / min;
[0321] f9 (retention time: 9.022 min; 65 mg);
[0322] f10 (retention time: 12.626 min; 60 mg).
[0323] Synthesis of intermediates f11-f12
[0324] Separation conditions: Chromatographic column: CHIRALPAK AS-H, 5*25 cm, 5 μm; Mobile phase A: Hex (0.4% TFA), Mobile phase B: MeOH; EtOH = 1:1, Flow rate: 20.0 mL / min;
[0325] f11 (retention time: 12.527 min; 83 mg);
[0326] f12 (retention time: 17.993 min; 82 mg).
[0327] Synthesis of intermediates f13-f14
[0328] Separation conditions: Chromatographic column: CHIRAL ART Cellulose-SB, 2*25 cm, 5 μm; Mobile phase A: Hex (0.4% DEA), Mobile phase B: Isopropanol, Flow rate: 20.0 mL / min;
[0329] f13 (retention time: 11.775 min; 140 mg);
[0330] f14 (retention time: 12.988 min; 140 mg).
[0331] Synthesis of intermediates f15-f16
[0332] Separation conditions: chromatographic column: Lux 5um Cellulose-4, 2.12*25cm, 5μm; mobile phase A: Hex (0.4% DEA), mobile phase B: isopropanol, flow rate: 20.0mL / min;
[0333] f13 (retention time: 8.451 min; 170 mg);
[0334] f14 (retention time: 10.379 min; 170 mg).
[0335] Synthesis of intermediates f17-f18
[0336] Separation conditions: Chromatographic column: CHIRALPAKAS3; Mobile phase A: Hex (0.1% TFA) / (MeOH:EtOH=1:1)=85 / 15; Flow rate: 1.0 mL / min;
[0337] f17 (retention time: 4.784 min; 82 mg);
[0338] f18 (retention time: 6.610 min; 80 mg).
[0339] Synthesis of intermediates f19-f20
[0340] Separation conditions: Chromatographic column: CHIRALPAK IF 2*25cm, 5μm; Mobile phase A: Hex (0.5% 2M NH3-MeOH), Mobile phase B: EtOH; Flow rate: 20mL / min;
[0341] F19 (retention time: 5.453 min; 160 mg);
[0342] F19 (retention time: 7.197 min; 170 mg).
[0343] Synthesis of intermediates f21-f22 (9.5g split)
[0344] Separation conditions: Chromatographic column: CHIRALPAK IF, 2*25 cm, 5 μm; Mobile phase A: Hex (0.5% 2 M NH3-MeOH), Mobile phase B: EtOH; Flow rate: 20 mL / min;
[0345] f21 (retention time: 21.302 min; 4.0 g);
[0346] f22 (retention time: 25.063 min; 4.5 g).
[0347] Synthesis of intermediate f23-f24 (10.1g split)
[0348] Separation conditions: Chromatographic column: UniChiral CNZ-5H, 2*25 cm, 5 μm; Mobile phase A: Hex (0.5% 2 M NH3-MeOH), Mobile phase B: EtOH; Flow rate: 25 mL / min;
[0349] f23 (retention time: 9.872 min; 4.1 g);
[0350] f24 (retention time: 15.440 min; 5.1 g).
[0351] Example 2: Synthesis of target molecules P1-P33 and control molecule A1
[0352] Procedure: Under nitrogen, intermediate a1 (100 mg, 0.61 mmol), 4-dimethylaminopyridine DMAP (225 mg, 1.84 mmol), and DIEA (396 mg, 3.1 mmol) were dissolved in 3 mL of dichloromethane. A dichloromethane solution of intermediate b1 (217 mg, 0.61 mmol, 0.5 mL) was added dropwise. The condensation reagent T3P (780 mg, 2.5 mmol) was also added. The mixture was reacted at room temperature for 12 hours. The solvent was evaporated under reduced pressure, and the crude product was separated by flash reverse-phase column chromatography (C18, CH3CN / H2O, 4 / 5) to obtain the target compound P1 (34 mg) in an 11% yield. LCMS ESI-MS m / z: 500 [M+H] + .
[0353] 1 H NMR (300MHz, DMSO-d6) δ10.64(d,J=45.5Hz,1H),8.89–8.68(m,3H),8.20–8.06(m,1H),7.82(d,J=32.6Hz,1H),7.70–7.42(m,2H),7.37(dt,J= 8.8,4.9Hz,1H),6.22(d,J=19.1Hz,2H),5.73(dq,J=41.0,7.0Hz,1H),5.29–4.63(m,2H),4.23(d,J=15.5Hz,3H),1.59(dd,J=30.7,7.0Hz,3H).
[0354] Referring to the synthetic route of compound P1, similar raw materials or intermediates were used (replacing a2 with intermediates a3-a5, a9-a21, a23-a30, a32-a35, a37-a40, f1-f2, f5-f12, f17-f18 or a43, etc.) to synthesize the following target molecules.
[0355] *Indicates chiral center, which was not resolved.
[0356] Example 3
[0357] MTAP-deficient cells are sensitive to PRMT5-MTA inhibitors due to the accumulation of MTA. However, MTAP wild-type (MTAP normal) cells do not accumulate MTA and are independent of PRMT5. By testing the activity of both, the inhibitory and selectivity of the molecules of the present invention for PRMT5 at the cellular level were demonstrated.
[0358] HCT116 wild-type and MTAP-deficient cells were cultured in MCCOYS 5A medium containing 10% FBS and 1% penicillin-streptomycin, placed in a 37°C, 5% CO2 constant temperature incubator, and 40 μL of cell suspension was added to each well of a 384-well microplate. 40 nL of compounds at different concentrations were added to each well using Echo and placed in a 37°C, 5% CO2 constant temperature incubator for 7-10 days. 40 μL of CTG solution (Promega, Cat No. G7573) was added to each well and placed in a 37°C, 5% CO2 constant temperature incubator incubated in the dark for 30 minutes. The luminescence value was read using an Envision multifunctional microplate reader (Perkin Elmer, catalog number Envision 2104). The light signal is proportional to the amount of ATP in the system, and the ATP content directly characterizes the number of viable cells in the system.
[0359] IC 50 Value calculation:
[0360] Y=lower platform signal+(upper platform signal-lower platform signal) / (1+10^((LogIC 50 -X) × Hill slope)
[0361] X: log value of compound concentration
[0362] Y: inhibition rate (%)
[0363] Table 1: 2D anti-proliferative effects of compounds on HTC116-MTAP del and wild type colorectal cancer HCT-116 cell lines.
[0364] ND = Not Tested
[0365] These experimental results demonstrate that the superior compounds of this invention exhibit significant anti-proliferative effects against MTAP-deficient tumor cells by inhibiting PRMT5, while exhibiting weaker inhibition against wild-type cells, potentially leading to a higher safety profile. Some of these compounds exhibited superior activity and selectivity compared to control molecules AM9747, TNG908, and GSK3326595.
[0366] The molecule of the present invention has the same or better activity than AM9747, but much higher selectivity than AM9747, and much higher activity and selectivity than TNG908.
[0367] Compared with the control molecule A1, P2a, P22, P29a and P32 proved that alkyl substitution (especially methyl substitution or deuterated methyl substitution) of this series of molecules is crucial for activity, so deuteration is beneficial to the improvement of metabolism and the activity is maintained longer.
[0368] Example 4
[0369] In-cell western blot analysis of arginine symmetric dimethylation inhibition
[0370] HCT116 wild-type or MTAP-deficient cells (HTC116-MTAP del) cultured in RPMI1640 medium containing 10% fetal bovine serum and 1% penicillin-streptomycin were seeded into 384-well microplates in a 30 μL culture volume and incubated overnight at 37°C, 5% CO2. 60 nL of compound at various concentrations was added to each well using ECHO and incubated at 37°C, 5% CO2 for 96 hours.
[0371] Then, 50 μL of 4% paraformaldehyde solution was added to each well and incubated at room temperature for 20 minutes to fix the cells. The solution in the wells was removed, and PBS solution containing 0.1% Tween 20 (PBST) was added to each well for washing 4 times. 30 μL of ice-cold methanol was added to each well and incubated at -20°C for 10 minutes; the methanol was removed and washed 4 times with PBST. 30 μL of Odyssey blocking solution containing 0.5% Tween 20 was added to each well and incubated at room temperature for 2 hours with shaking; the blocking solution was removed, and 30 μL of primary antibody (Symmetric Di-Methyl Arginine Motif [sdme-RG] MultiMab) diluted 1:500 in Odyssey blocking solution containing 0.5% Tween 20 was added to each well. TM Rabbit mAb mix) at 4°C overnight. Remove the primary antibody, and wash each well four times with PBST for 5 minutes each. Add a secondary antibody (goat anti-rabbit IRDye 800CW, 1:800) and a nuclear stain (DRAQ5, 1:10,000) diluted in Odyssey blocking buffer containing 0.5% Tween 20 to each well and incubate at room temperature for 2 hours in the dark. Remove the secondary antibody and wash four times with PBST.
[0372] The sdme-RG and DRAQ5 signals were scanned at 800 nm and 700 nm, respectively, using a Li-Cor Odyssey instrument and the signal values were recorded. The sdme-RG / DRAQ5 ratio was used to calculate the inhibition percentage of arginine symmetric dimethylation (SDMA), and the IC was calculated using GraphPad Prism software. 50 value.
[0373] Table 1: Inhibitory effects of compounds on arginine symmetric methylation in HTC116-MTAP del and wild type colorectal cancer HCT-116 cell lines
[0374] ND = Not Tested
[0375] The above experimental results show that the excellent compound of the present invention has a significant inhibitory effect on arginine symmetric methylation in MTAP-deficient tumor cells by inhibiting PRMT5, while the inhibition is weaker on the wild type.
[0376] The molecule of the present invention has the same or better activity than AM9747, but has much higher selectivity than AM9747 and much higher activity than TNG908.
[0377] Example 5:
[0378] The compound's liver microsome stability test is as follows:
[0379] The compounds of the present invention were subjected to a liver microsome stability test. The test compounds were co-incubated with liver microsomes of different species with or without the addition of NADPH. The final concentration of the test compound in the test system was 1 μM, the final concentration of NADPH was 1 mM, and the final concentration of liver microsomes was 0.5 mg / mL. The concentration of the compound in the incubation supernatant at different time points within 60 minutes was measured and the pharmacokinetic parameters (such as clearance Cl) were calculated. int ).
[0380] This result indicates that the molecules of the present invention have good metabolic stability (especially in the human body). Some molecules have a lower clearance rate in human liver microsome metabolism than AMG9747, resulting in slower metabolism in the human body.
[0381] ND = Not Tested
[0382] The above results indicate that the molecules of the present invention have good metabolic stability in liver microsomes. The deuterated compounds P22 and P32 maintain or improve metabolism compared to the non-deuterated molecules P2a or P29a, and are expected to have good in vivo exposure when administered in vivo.
[0383] Example 6:
[0384] Membrane permeability evaluation experiment: Caco-2 assays
[0385] The membrane permeability of the molecules of the present invention will be evaluated. Samples will be analyzed by LC-MS to estimate the apparent permeability coefficient (P) of the compounds in Caco-2 monolayer cells. app ), where the pH of the apical compartment is 6.5 and the pH of the basolateral compartment is 7.4. Active efflux transport of compounds was blocked by inhibitors of the P-gp efflux transporter, BCRP, and MRP2 (50 μM quinidine, 30 μM benzbromarone, and 20 μM sulfasalazine). Data were used to calculate the apparent permeability (Papp).
[0386] P app =(V A ×[drug] acceptor ) / (Area×Time×[drug]initial,donor)
[0387] Where V A is the volume of the receptor pore (unit: mL), Area is the surface area of the membrane (0.143 cm for Transwell-96 well permeable support) 2 ), time is the total transport time (in seconds).
[0388] Efflux Ratio=P app ( B-A ) / P app ( A-B )
[0389] The Caco-2 membrane permeation data of the molecule of the present invention are as follows:
[0390] The above results indicate that the molecule of the present invention has good membrane permeability and is expected to achieve good tumor inhibition effects with better in vivo pharmacokinetic properties.
[0391] Membrane permeability evaluation experiment: MDCK-MDR1 assays
[0392] The membrane permeability of the molecules of the present invention is evaluated to predict the permeability of the molecules to the brain.
[0393] The details are as follows: 1. Incubate MDCK-MDR1 cells in advance, density: 1.56*10 6 cells / mL, seeded in 96-well plates, and cultured at 37°C for 7 days. 2. Remove the MDCKII-MDR1 plates from the incubator, wash twice with prewarmed HBSS (10 mM HEPES, pH 7.4), and then incubate at 37°C for 30 minutes. 3. Dilute the stock solution of the test compound with DMSO to a 0.2 mM solution, which is then diluted with HBSS (10 mM HEPES, pH 7.4) to a 1 μM working solution. A blank control group was diluted with DMSO to a 0.2 mM solution, which was then diluted with HBSS (10 mM HEPES, pH 7.4) to a 1 μM working solution. The final DMSO concentration in the culture system was 0.5%. 4. Determine the rate of drug transport from the apical to basolateral direction. Add 125 μL of a 1 μM test compound solution to the Transwell insert (top chamber), and immediately transfer a 50 μL sample (D0 sample) from the top chamber to a new 96-well plate. Fill the receiver plate wells (basolateral compartment) with 235 μL of HBSS (10 mM HEPES, pH 7.4) and incubate at 37°C for 2 hours. 5. At the end of the incubation period, transfer 50 μL of each donor and acceptor sample to a new well of a 96-well plate and add 4 volumes of cold acetonitrile containing the appropriate internal standard (IS). Before LC-MS / MS analysis, mix 100 μL of the supernatant with an appropriate volume of ultrapure water.
[0394] P app =(V A ×[drug] acceptor ) / (Area×Time×[drug]initial,donor)
[0395] Where V A is the volume of the receptor pore (unit: mL), Area is the surface area of the membrane (0.143 cm for Transwell-96 well permeable support) 2 ), time is the total transport time (in seconds).
[0396] Efflux Ratio=P app ( B-A ) / P app ( A-B )
[0397] The MDCK-MDR1 membrane permeation data of the molecule of the present invention are as follows:
[0398] The above results indicate that most molecules of the present invention have good membrane permeability. The deuterated compounds P22 and P32 have lower efflux rates than the non-deuterated molecules P2a or P29a, and are expected to have higher brain concentrations when administered in vivo.
[0399] Example 7:
[0400] Mouse pharmacokinetic evaluation experiment
[0401] CD1 female mice were used as test animals and the drug was administered orally / intravenously (oral dosage: 10 mg / kg, intravenous dosage: 2 mg / kg).
[0402] Experimental plan: Oral administration consisted of 3 mice per group, and intravenous administration consisted of 3 mice per group. For oral administration, plasma samples were collected before (0 h) and after (0.25, 0.5, 1, 2, 4, 8, and 24 h) administration. For intravenous administration, plasma samples were collected before (0 h) and after (0.083, 0.25, 0.5, 1, 2, 4, 8, and 24 h) administration. The plasma concentrations of the drug were determined by LC / MS / MS after oral and intravenous administration. The collected data were calculated using AB Sciex QTRAP 6500 software. The experimental results are as follows:
[0403] The above experimental results show that the compound of the present invention has good oral absorption effect and high in vivo exposure. Due to its better selectivity than reported molecules, such as GSK3326595, it is expected to bring higher therapeutic effects.
[0404] In addition, the comparison of compounds P2a and P22 showed that after the methyl group of compound P2a was replaced by deuterium, P22 had a slower clearance rate in vivo, a longer half-life, and a higher C max, higher in vivo exposure, so the deuterated compound P22 is better than P2a.
[0405] Similarly, after the P32 molecule is deuterated, it also has a higher in vivo exposure.
[0406] Example 8:
[0407] hERG experimental test
[0408] The CHO heg-duo cell line stably expressing the hERG channel was purchased from B'SYS GmbH and screened for monoclonal activity using a patch-clamp platform from Beijing Kanglong Chemical Co., Ltd. Cells were cultured in F12 (HAM) medium containing 10% fetal bovine serum, 100 U / mL penicillin-streptomycin, 100 μg / mL hygromycin, and 100 μg / mL G418.
[0409] The membrane was depolarized to +30 mV for 4.8 seconds, then the voltage was restored to -50 mV for 5.2 seconds to remove inactivation and measure the inactivation tail current. The sampling interval was 15 seconds. The maximum amount of tail current magnitude was used to determine the hERG current amplitude.
[0410] Blank vector was applied to the cells to establish a baseline. After the hERG current was stabilized for at least 5 minutes, the specimens were perfused. In the presence of the test compound, the hERG current at different working concentrations was recorded for no less than 5 minutes to reach steady state, and then 5 scans were captured. If steady state was not reached within 10 minutes, the average peak current of the last 5 sweeps was used instead of the steady state value. Cisapride was used as a positive control in the experiment. The inhibitory effect of the test article on hERG current was tested at 5 concentrations in 2 independent experiments (n=2) to determine the IC 50 .
[0411] Calculation formula:
[0412] The above results show that the molecules of the present invention have a weak effect on the heart, and the deuterated compound P32 is safer than the molecule P29a.
[0413] Example 9:
[0414] In vivo efficacy experiments were conducted on BALB / c nude mice. Details are as follows:
[0415] NCI-H838 (MTAPdel) non-small cell lung adenocarcinoma tumor cells were cultured and inoculated subcutaneously into 6-8 week old female BALB / c nude mice (weighing approximately 20 g). The mice were cultured in an SPF-grade experimental environment and all mice had free access to a commercially certified standard diet. When the average tumor volume of the mice grew to 140 mm 3 Around 24 hours after the start of treatment, the test compound was orally administered daily. The dosage was as follows: blank group vehicle (Saline containing 0.1% Tween 80 and 0.5% methyl cellulose). The dosage of the treatment group was 75 mg / kg or 100 mg / kg, twice daily. Tumor volume was measured three times a week using a two-dimensional caliper, and the animals were weighed daily. After 23 consecutive days of administration, the inhibition rate (TGI / 100%) was calculated based on the final tumor volume. The volume calculation formula is: V = 1 / 2a*b 2 , a represents the long diameter of the tumor, and b represents the short diameter of the tumor.
[0416] The results indicate that the molecule of the present invention has good in vivo efficacy against MTAP-deficient tumor cells at different doses and has low toxicity to mice.
[0417] TGI = [1-[volume of the drug administration group (D23-D1) / volume of the blank group (D23-D1)]]*100%
[0418] Example 10:
[0419] In vivo efficacy experiments were conducted on BALB / c nude mice. Details are as follows:
[0420] HUP-T4 (MTAPdel) human pancreatic cancer cells were cultured in MEM medium containing 10% fetal bovine serum and inoculated subcutaneously into 6-8 week old female BALB / c nude mice (weighing approximately 25 g). The mice were cultured in an SPF-grade experimental environment and had free access to a commercially certified standard diet. When the average tumor volume of the mice grew to 176 mm, the mice were randomly assigned to receive the MTAPdel. 3 Around 24 hours after the start of treatment, the test compound was orally administered daily. The dosage was as follows: blank group vehicle (0.1% TW80 + 0.5% methylcellulose + 99.4% saline). The dosage of the treatment group was 75 mg / kg or 50 mg / kg, twice a day. The tumor volume was measured three times a week with a two-dimensional caliper, and the animals were weighed every day. After 28 days of continuous administration, the inhibition rate (TGI / 100%) was calculated based on the final tumor volume. The volume calculation formula is: V = 1 / 2a*b 2 , a represents the long diameter of the tumor, and b represents the short diameter of the tumor.
[0421] The results indicate that the molecules of the present invention have good in vivo efficacy against MTAP-deficient pancreatic cancer cells and can cause tumor regression.
[0422] TGI = [1-[volume of the drug administration group (D28-D1) / volume of the blank group (D28-D1)]]*100%
Claims
1. A compound of formula (I), or a pharmaceutically acceptable salt, isotopic variant, tautomer or stereoisomer thereof: Wherein, X1, X2, and X3 are each independently selected from -CH=, -O-, -S-, -N=, or -NH-, and at least one of X1, X2, and X3 is -N= or -NH-, and the circle represents aromaticity; R1 is selected from H, C 1-6 alkyl, deuterated C 1-6 alkyl, C 3-6 cycloalkyl or C 1-6 haloalkyl; R2 is selected from H, C 1-6 alkyl or halogen; R3 and R4 are independently selected from H, C 1-6 alkyl, C 3-6 cycloalkyl or a 4- to 10-membered heterocyclic group, wherein the C in R3 or R4 1-6 alkyl, C 3- cycloalkyl or 4- to 10-membered heterocyclic group is each optionally substituted by one or two R5, where R5 is selected from hydrogen, deuterium, halogen, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, CN, SF5, C 3-6 cycloalkyl, -S(O)2CF3, -OCF3, -SCF3, -SCH3 or a 5- to 10-membered heteroaryl; the 5- to 10-membered heteroaryl is optionally further substituted by R6, where R6 is selected from H, CN, halogen, C 1-6 alkyl, C 1-6 haloalkyl, SF5, OR a or a 5- to 6-membered heteroaryl, the 5- to 6-membered heteroaryl being optionally substituted by one, two or three R z substituents; Alternatively, R3, R4 and the nitrogen atom to which they are attached together form a 4- to 10-membered heterocyclic group, the 4- to 10-membered heterocyclic group containing 0 or 1 additional heteroatom selected from oxygen, nitrogen or sulfur, and the 4- to 10-membered heterocyclic group being optionally substituted by 1, 2, 3 or 4 R x substituents; R x selected from C 1-6 alkyl, C 1-6 haloalkyl, phenyl or a 5- to 10-membered heteroaryl, wherein the phenyl or 5- to 10-membered heteroaryl is optionally substituted with one, two or three R y substituents; R y Selected from halogen, C 1-6 alkyl, C 1-6 haloalkyl, SF5, CN, OR a , C 1-6 alkoxy, -NR z1 R z2 , NR z1 R z2 -C 1-6 alkyl-, C 3-6 cycloalkyl, 4- to 12-membered heterocyclic group or 5- to 10-membered heteroaryl group, wherein the 4- to 12-membered heterocyclic group or 5- to 10-membered heteroaryl group is optionally substituted with one, two or three R z substituents; R z selected from C 1-6 alkyl, halogen, CN, C 1-6 haloalkyl or C 1-6 alkoxy; R a selected from H, C 1-6 alkyl or C 1-6 haloalkyl; R z1 and R z2 each independently selected from H or C 1-6 alkyl; and n is 0, 1, or 2.
2. The compound of claim 1, or a pharmaceutically acceptable salt, isotope variant, tautomer or stereoisomer thereof, which is a compound of formula (II a ) or formula (II b ): Wherein, R1 is selected from H, C 1-6 alkyl, deuterated C 1-6 alkyl, C 3-6 cycloalkyl or C 1-6 haloalkyl; R2 is selected from H, C 1-6 alkyl or halogen; R3 and R4 are independently selected from H, C 1-6 alkyl, C 3-6 cycloalkyl or a 4- to 10-membered heterocyclic group, wherein the C in R3 or R4 1-6 alkyl, C 3- cycloalkyl or 4- to 10-membered heterocyclic group is each optionally substituted by one or two R5, wherein R5 is selected from hydrogen, deuterium, halogen, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, CN, SF5, C 3-6 cycloalkyl, -S(O)2CF3, -OCF3, -SCF3, -SCH3 or a 5- to 10-membered heteroaryl; the 5- to 10-membered heteroaryl is optionally further substituted by R6, wherein R6 is selected from H, CN, halogen, C 1-6 alkyl, C 1-6 haloalkyl, SF5, OR a or a 5- to 6-membered heteroaryl, the 5- to 6-membered heteroaryl being optionally substituted by one, two or three R z sub substitution; Alternatively, R3, R4 and the nitrogen atom to which they are attached together form a 4- to 10-membered heterocyclic group, said 4- to 10-membered heterocyclic group containing 0 or 1 additional heteroatom selected from oxygen, nitrogen or sulfur, and said 4- to 10-membered heterocyclic group being optionally substituted with 1, 2, 3 or 4 R x substituents; R x selected from C 1-6 alkyl, C 1-6 haloalkyl, phenyl or a 5- to 10-membered heteroaryl, wherein the phenyl or 5- to 10-membered heteroaryl is optionally substituted by one, two or three R y substituents; R y Selected from halogen, C 1-6 alkyl, C 1-6 haloalkyl, SF5, CN, OR a , C 1-6 alkoxy, -NR z1 R z2 , NR z1 R z2 -C 1-6 alkyl-, C 3-6 cycloalkyl, a 4- to 12-membered heterocyclic group or a 5- to 10-membered heteroaryl group, wherein the 4- to 12-membered heterocyclic group or the 5- to 10-membered heteroaryl group is optionally substituted with one, two or three R z substituents; R z selected from C 1-6 alkyl, halogen, CN, C 1-6 haloalkyl or C 1-6 alkoxy; R a selected from H, C 1-6 alkyl or C 1-6 haloalkyl; and R z1 and R z2 each independently selected from H or C 1-6 alkyl group 3. A compound according to claim 1 or 2, or a pharmaceutically acceptable salt, isotope variant, tautomer or stereoisomer thereof, having the following structure: Wherein: R1 is selected from H, C 1-6 alkyl, deuterated C 1-6 alkyl, C 3-6 cycloalkyl or C 1-6 haloalkyl; R2 is selected from H, methyl, Cl, or F; R 5a or R 5b each independently selected from 5- to 10-membered heteroaryl; said 5- to 10-membered heteroaryl is optionally substituted with R6, and R6 is selected from H, CN, halogen, C 1-6 alkyl, C 1-6 haloalkyl, SF5, OR a or 5- to 6-membered heteroaryl; said 5- to 6-membered heteroaryl is optionally substituted with one, two or three R z substituents; R x1 selected from phenyl or 5- to 10-membered heteroaryl, wherein the phenyl or 5- to 10-membered heteroaryl is optionally substituted with one, two or three R y substituents; R y Selected from halogen, C 1-6 alkyl, C 1-6 haloalkyl, SF5, CN, OR a , C 1-6 alkoxy, -NR z1 R z2 , NR z1 R z2 -C 1-6 alkyl-, C 3-6 cycloalkyl, 4- to 12-membered heterocyclic group or 5- to 10-membered heteroaryl group, wherein the 4- to 12-membered heterocyclic group or 5- to 10-membered heteroaryl group is optionally substituted with 1, 2 or 3 R z substituents; R z selected from C 1-6 alkyl, halogen, CN, C 1-6 haloalkyl or C 1-6 alkoxy; R a selected from H, C 1-6 alkyl or C 1-6 haloalkyl; R x2 selected from C 1-6 alkyl or C 1-6 haloalkyl; R z1 and R z2 each independently selected from H or C 1-6 alkyl; and Y is selected from O, S, or CH2.
4. A compound according to claim 1 or 2, or a pharmaceutically acceptable salt, isotope variant, tautomer or stereoisomer thereof, having the following structure: Wherein: R1 is selected from H, C 1-6 alkyl, deuterated C 1-6 alkyl, C 3-6 cycloalkyl or C 1-6 haloalkyl; R2 is selected from H, methyl, Cl, or F; R3 is selected from H, C 1-6 alkyl, deuterated C 1-6 alkyl, C 3-6 cycloalkyl or a 4- to 10-membered heterocyclic group; the C 1-6 alkyl or 4- to 10-membered heterocyclic group is optionally substituted by one or two R5; R5 is selected from hydrogen, deuterium, halogen, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, CN, SF5, C 3-6 cycloalkyl, -S(O)2CF3, -OCF3, -SCF3, -SCH3 or a 5- to 10-membered heteroaryl; the 5- to 10-membered heteroaryl is optionally further substituted by R6, and R6 is selected from H, CN, halogen, C 1-6 alkyl, C 1-6 haloalkyl, SF5, OR a or a 5- to 6-membered heteroaryl; the 5- to 6-membered heteroaryl is optionally substituted by 1, 2 or 3 R z substituents; R z selected from C 1-6 alkyl, halogen, CN, C 1-6 haloalkyl or C 1-6 alkoxy; R a selected from H, C 1-6 alkyl or C 1-6 haloalkyl; Y is selected from NH, O, S, or CH2; and Z is selected from N or CH. A compound according to any one of claims 1-3, or a pharmaceutically acceptable salt, isotope variant, tautomer or stereoisomer thereof, having the following structure: Wherein, R1 is selected from C 1-6 alkyl, C 3-6 cycloalkyl or C 1-6 haloalkyl; R 5a or R 5b each independently selected from 5- to 10-membered heteroaryl; said 5- to 10-membered heteroaryl is optionally substituted with R6, and R6 is selected from H, CN, halogen, C 1-6 alkyl, C 1-6 haloalkyl, SF5, OR a or 5- to 6-membered heteroaryl; said 5- to 6-membered heteroaryl is optionally substituted with one, two or three R z substituents; R x1 selected from phenyl or a 5- to 10-membered heteroaryl, wherein the phenyl or 5- to 10-membered heteroaryl is optionally substituted with one, two or three R y substituents; R y Selected from halogen, C 1-6 alkyl, C 1-6 haloalkyl, SF5, CN, OR a , C 1-6 alkoxy, -NR z1 R z2 , NR z1 R z2 -C 1-6 alkyl-, C 3-6 cycloalkyl, a 4- to 12-membered heterocyclic group or a 5- to 10-membered heteroaryl group, wherein the 4- to 12-membered heterocyclic group or 5- to 10-membered heteroaryl group is optionally substituted by 1, 2 or 3 R z substituents; R z selected from C 1-6 alkyl, halogen, CN, C 1-6 haloalkyl or C 1-6 alkoxy; R a selected from H, C 1-6 alkyl or C 1-6 haloalkyl; and R z1 and R z2 each independently selected from H or C 1-6 alkyl group.
6. The compound of claim 5, or a pharmaceutically acceptable salt, isotope variant, tautomer or stereoisomer thereof, which is a compound of formula (III-1): Wherein, R1 is selected from methyl, CD3, ethyl, or cyclopropyl; R 5a or R 5b each independently selected from 6-membered heteroaryl; said 6-membered heteroaryl is optionally further substituted with R6, and R6 is selected from H, CN, Halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, SF5, OR a or a 5- or 6-membered heteroaryl; said 5- or 6-membered heteroaryl is optionally substituted with 1, 2 or 3 R z substituents; R z selected from C 1-6 alkyl, halogen, CN, C 1-6 haloalkyl or C 1-6 alkoxy; and R a selected from H, C 1-6 alkyl or C 1-6 haloalkyl.
7. The compound of claim 6, or a pharmaceutically acceptable salt, isotope variant, tautomer or stereoisomer thereof, which is a compound of formula (III-2): R1 is selected from methyl, ethyl, or cyclopropyl; R 5b For Optionally, it is further substituted by R6, and R6 is selected from H, CN, halogen, C 1-6 alkyl, C 1-6 haloalkyl, SF5, OR a or 5- or 6-membered heteroaryl; the 5- or 6-membered heteroaryl is optionally substituted by one, two or three R z substituents; R z selected from C 1-6 alkyl, halogen, CN, C 1-6 haloalkyl or C 1-6 alkoxy; and R a selected from H, C 1-6 alkyl or C 1-6 haloalkyl.
8. The compound of claim 7, or a pharmaceutically acceptable salt, isotope variant, tautomer or stereoisomer thereof, which is a compound of formula (III-3): R1 is selected from methyl, CD3, ethyl, or cyclopropyl; R6 is selected from H, CN, halogen, C 1-6 alkyl, C 1-6 haloalkyl, SF5, OR a or 5- or 6-membered heteroaryl; the 5- or 6-membered heteroaryl is optionally substituted with one, two or three R z substituents; R z selected from C 1-6 alkyl, halogen, CN, C 1-6 haloalkyl or C 1-6 alkoxy; and R a selected from H, C 1-6 alkyl or C 1-6 haloalkyl.
9. The compound of claim 5, or a pharmaceutically acceptable salt, isotope variant, tautomer or stereoisomer thereof, which is a compound of formula (IV-1): Wherein, R1 is selected from C 1-6 alkyl, deuterated C 1-6 alkyl, C 3-6 cycloalkyl or C 1-6 haloalkyl; R x1 selected from phenyl or 5- to 10-membered heteroaryl, wherein the phenyl or 5- to 10-membered heteroaryl is optionally substituted with one, two or three R y Take substitution; R y Selected from halogen, C 1-6 alkyl, C 1-6 haloalkyl, SF5, CN, OR a , C 1-6 alkoxy, C 3-6 cycloalkyl, A 4- to 12-membered heterocyclic group or a 5- to 10-membered heteroaryl group, wherein the 4- to 12-membered heterocyclic group or 5- to 10-membered heteroaryl group is optionally substituted with one, two or three R z substituted; R z selected from C 1-6 alkyl, halogen, CN, C 1-6 haloalkyl or C 1-6 alkoxy; and R a selected from H, C 1-6 alkyl or C 1-6 haloalkyl.
10. The compound of claim 9, or a pharmaceutically acceptable salt, isotope variant, tautomer or stereoisomer thereof, which is a compound of formula (IV-2): Wherein, R1 is selected from methyl, CD3, ethyl, or cyclopropyl; R y selected from C 1-6 alkyl, C 1-6 haloalkyl, CN, OR a , C 1-6 alkoxy, C 3-6 cycloalkyl, A 4- to 12-membered heterocyclic group or a 5- to 10-membered heteroaryl group, wherein the 4- to 12-membered heterocyclic group or 5- to 10-membered heteroaryl group is optionally substituted with one, two or three Rs z and; R z selected from C 1-6 alkyl, halogen, CN, C 1-6 haloalkyl or C 1-6 alkoxy group.
11. The compound of claim 5, or a pharmaceutically acceptable salt, isotope variant, tautomer or stereoisomer thereof, which is a compound of formula (V-1): Wherein, R1 is selected from C 1-6 alkyl, deuterated C 1-6 alkyl, C 3-6 cycloalkyl or C 1-6 haloalkyl; R x1 is a 5- to 10-membered heteroaryl which is optionally substituted by one, two or three R y substituents; R y Selected from halogen, C 1-6 alkyl, C 1-6 haloalkyl, SF5, CN, OR a , C 1-6 alkoxy, C 3-6 cycloalkyl, 4- to 12-membered heterocyclic group or 5- to 10-membered heteroaryl, wherein the 5- to 10-membered heteroaryl is optionally substituted by one, two or three R z substituents; R z selected from C 1-6 alkyl, halogen, CN, C 1-6 haloalkyl or C 1-6 alkoxy; and R a selected from H, C 1-6 alkyl or C 1-6 haloalkyl.
12. The compound of claim 11, or a pharmaceutically acceptable salt, isotopic variant, tautomer or stereoisomer thereof, which is a compound of formula (V-2): Wherein, R1 is selected from methyl, CD3, ethyl, or cyclopropyl; R y Selected from halogen, C 1-6 alkyl, C 1-6 haloalkyl, SF5, CN, OR a , C 1-6 alkoxy, C 3-6 cycloalkyl, 4- to 12-membered heterocyclic group or 5- to 10-membered heteroaryl, wherein the 5- to 10-membered heteroaryl is optionally substituted by 1, 2 or 3 R z substituents; R z selected from C 1-6 alkyl, halogen, CN, C 1-6 haloalkyl or C 1-6 alkoxy; and R a selected from H, C 1-6 alkyl or C 1-6 haloalkyl.
13. The compound of claim 12, or a pharmaceutically acceptable salt, isotopic variant, tautomer or stereoisomer thereof, which is a compound of formula (V-3): Wherein, R1 is selected from methyl, CD3, ethyl, or cyclopropyl; R z selected from C 1-6 alkyl, halogen, CN, C 1-6 haloalkyl or C 1-6 alkoxy; and R a selected from H, C 1-6 alkyl or C 1-6 haloalkyl.
14. The compound of claim 4, or a pharmaceutically acceptable salt, isotopic variant, tautomer or stereoisomer thereof, having the following structure: Wherein: R1 is selected from H, C 1-6 alkyl, deuterated C 1-6 alkyl, C 3-6 cycloalkyl or C 1-6 haloalkyl; R3 is selected from H, C 1-6 alkyl, deuterated C 1-6 alkyl, C 3-6 cycloalkyl or a 4- to 10-membered heterocyclic group; the C 1-6 alkyl or 4- to 10-membered heterocyclic group is optionally substituted by one or two R5; R5 is selected from hydrogen, deuterium, halogen, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, CN, SF5, C 3-6 cycloalkyl, -S(O)2CF3, -OCF3, -SCF3, -SCH3 or a 5- to 10-membered heteroaryl; the 5- to 10-membered heteroaryl is optionally further substituted by R6, and R6 is selected from H, CN, halogen, C 1-6 alkyl, C 1-6 haloalkyl, SF5, OR a or a 5- to 6-membered heteroaryl; R a selected from H, C 1-6 alkyl or C 1-6 haloalkyl; and Z is selected from N or CH.
15. The compound of claim 14, or a pharmaceutically acceptable salt, isotopic variant, tautomer or stereoisomer thereof, having the following structure: Wherein: R1 is selected from H, methyl, deuterated methyl, ethyl, or cyclopropyl; R3 is selected from H, C 1-6 alkyl, deuterated C 1-6 alkyl, C 3-6 cycloalkyl or a 4- to 10-membered heterocyclic group; and R5 is selected from hydrogen, halogen, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, CN, SF5, C 3-6 cycloalkyl, -S(O)2CF3, -OCF3, -SCF3, -SCH3 or a 5- to 10-membered heteroaryl group.
16. The compound of claim 15, or a pharmaceutically acceptable salt, isotopic variant, tautomer, or stereoisomer thereof, wherein: R1 is selected from H, methyl, CD3, ethyl, or cyclopropyl; R3 is selected from H, methyl, CD3, ethyl, or cyclopropyl; and R5 is selected from hydrogen, F, Cl, Br, methyl, ethyl, methoxy, trifluoromethyl, difluoromethyl, CN, SF5, cyclopropyl, -S(O)2CF3, -OCF3, -OCF2Cl, -SCF3, -SCH3, or pyridyl.
17. A compound, or a pharmaceutically acceptable salt, isotope variant, tautomer or stereoisomer thereof, wherein the compound is selected from:
18. A pharmaceutical composition comprising the compound of any one of claims 1-17, or a pharmaceutically acceptable salt, isotopic variant, tautomer, or stereoisomer thereof, and a pharmaceutically acceptable excipient; preferably, it further comprises other therapeutic agents.
19. Use of the compound of any one of claims 1-17, or a pharmaceutically acceptable salt, isotopic variant, tautomer, or stereoisomer thereof, in the preparation of a drug for treating and / or preventing diseases mediated by PRMT5 methyltransferase.
20. A method for treating and / or preventing diseases mediated by PRMT5 methyltransferase in a subject, the method comprising administering to the subject the compound of any one of claims 1-17, or a pharmaceutically acceptable salt, isotopic variant, tautomer, or stereoisomer thereof, or the pharmaceutical composition of claim 18.
21. The compound of any one of claims 1-17, or a pharmaceutically acceptable salt, isotopic variant, tautomer, or stereoisomer thereof, or the pharmaceutical composition of claim 18, for treating and / or preventing diseases mediated by PRMT5 methyltransferase.
22. Use of the use according to claim 19 or the method according to claim 20 or the compound or composition according to claim 17, wherein the disease mediated by the PRMT5 methyltransferase is cancer, and the cancer is selected from: acoustic neuroma, adenocarcinoma, adrenal cancer, anal cancer, angiosarcoma (such as lymphangiosarcoma, lymphangioendotheliosarcoma, hemangioma), appendiceal cancer, benign monoclonal gammopathy, cholangiocarcinoma, bladder cancer, brain cancer (such as meningioma, glioma, such as astrocytoma, oligodendroglioma, medulloblastoma), bronchial cancer, carcinoid tumor, cervical cancer (such as cervical adenocarcinoma), choriocarcinoma, chordoma, craniopharyngioma, colorectal cancer (such as colon cancer, rectal cancer, colorectal adenocarcinoma), epithelial cancer, ependymoma, endothelial sarcoma (such as Kaposi's sarcoma, multiple idiopathic hemorrhagic sarcoma), endometrial cancer (such as uterine cancer, uterine sarcoma), esophageal cancer (such as esophageal adenocarcinoma, Barrett's adenocarcinoma), Ewing's sarcoma, eye cancer (such as intraocular melanoma, retinoblastoma), eosinophilia, gallbladder cancer, gastric cancer (such as gastric adenocarcinoma), gastrointestinal stromal tumor (GIST), head and neck cancer (such as head and neck squamous cell carcinoma, oral cancer (such as oral squamous cell carcinoma, laryngeal cancer (such as laryngeal cancer, pharyngeal cancer, nasopharyngeal cancer, oropharyngeal cancer))), hematopoietic system cancer (such as leukemia, such as acute lymphoblastic leukemia (ALL) (such as, B-cell ALL, T-cell ALL), acute myeloid leukemia (AML) (such as, B-cell AML, T-cell AML), chronic myeloid leukemia (CML) (such as, B-cell CML, T-cell CML), chronic lymphocytic leukemia (CLL) (such as, B-cell CLL, T-cell CLL), follicular lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), marginal zone B-cell lymphoma (such as mucosa-associated lymphoid tissue (MALT) lymphoma, nodal marginal zone B-cell lymphoma, splenic marginal zone B-cell lymphoma), primary mediastinal B-cell lymphoma, Burkitt lymphoma, lymphoplasmacytic lymphoma, hairy cell leukemia (HCL), immunoblastic large cell lymphoma, precursor B lymphoblastic lymphoma, and primary central nervous system (CNS) lymphoma; and T-cell non-Hodgkin lymphoma, such as precursor T lymphoblastic lymphoma / leukemia, peripheral T-cell lymphoma (such as cutaneous T-cell lymphoma (such as mycosis fungoides, Sézary syndrome), angioimmunoblastic T-cell lymphoma, extranodal natural killer T-cell lymphoma, enteropathy-type T-cell lymphoma, subcutaneous panniculitis-like T-cell lymphoma, anaplastic large cell lymphoma); a mixture of one or more of the above leukemias / lymphomas;Multiple myeloma (MM), heavy chain diseases (such as alpha chain disease, gamma chain disease, mu chain disease), hemangioblastoma, inflammatory myofibroblastic tumor, immunocytic amyloidosis, renal cancer (such as nephroblastoma, renal cell carcinoma), liver cancer (such as hepatocellular carcinoma, malignant hepatocellular carcinoma), lung cancer (such as bronchial carcinoma, small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), lung adenocarcinoma, leiomyosarcoma (LMS), mastocytosis (such as systemic mastocytosis), myelodysplastic syndrome (MDS), mesothelioma, myeloproliferative diseases (MPD) (such as polycythemia vera (PV), essential thrombocythemia (ET), idiopathic myelofibrosis with extramedullary hematopoiesis (AMM), chronic idiopathic myelofibrosis, chronic myelogenous leukemia (CML), chronic neutrophilic leukemia (CNL), hypereosinophilic syndrome (HES), neuroblastoma, neurofibroma (such as neurofibromatosis type 1 or type 2, schwannomatosis), neuroendocrine carcinoma (such as gastroenteropancreatic neuroendocrine tumor (GEP-NET), carcinoid tumor), osteosarcoma, ovarian cancer (such as cystadenocarcinoma, ovarian embryonal carcinoma, ovarian adenocarcinoma), papillary adenocarcinoma or penile cancer.;
